

Review

# Natural Products–Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry

Guo-Qing Chen <sup>1,†</sup>, Hong-Yan Guo <sup>1,†</sup>, Zhe-Shan Quan <sup>1</sup>, Qing-Kun Shen <sup>1</sup>, Xiaoting Li <sup>1,\*</sup> and Tian Luan <sup>2,\*</sup> 

<sup>1</sup> Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China; 2022010882@ybu.edu.cn (G.-Q.C.); hongyanguo@ybu.edu.cn (H.-Y.G.); zsqun@ybu.edu.cn (Z.-S.Q.); qkshen@ybu.edu.cn (Q.-K.S.)

<sup>2</sup> Department of Pharmacy, Shenyang Medical College, Shenyang 110034, China

\* Correspondence: luantian@symc.edu.cn (T.L.); 0000008735@ybu.edu.cn (X.L.)

† These authors contributed equally to this work.

**Abstract:** Pyrazine is a six-membered heterocyclic ring containing nitrogen, and many of its derivatives are biologically active compounds. References have been downloaded through Web of Science, PubMed, Science Direct, and SciFinder Scholar. The structure, biological activity, and mechanism of natural product derivatives containing pyrazine fragments reported from 2000 to September 2023 were reviewed. Publications reporting only the chemistry of pyrazine derivatives are beyond the scope of this review and have not been included. The results of research work show that pyrazine-modified natural product derivatives have a wide range of biological activities, including anti-inflammatory, anticancer, antibacterial, antiparasitic, and antioxidant activities. Many of these derivatives exhibit stronger pharmacodynamic activity and less toxicity than their parent compounds. This review has a certain reference value for the development of heterocyclic compounds, especially pyrazine natural product derivatives.

**Keywords:** natural products; pyrazine; pharmacological activities



**Citation:** Chen, G.-Q.; Guo, H.-Y.; Quan, Z.-S.; Shen, Q.-K.; Li, X.; Luan, T. Natural Products–Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry. *Molecules* **2023**, *28*, 7440. <https://doi.org/10.3390/molecules28217440>

Academic Editor: Steven Fletcher

Received: 13 October 2023

Revised: 2 November 2023

Accepted: 3 November 2023

Published: 5 November 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

Heterocyclic structures are common in clinical drugs used to treat diseases. Such drugs typically contain nitrogen, oxygen, and sulfur, which can accept electrons and form hydrogen bonds. These properties enhance the target binding ability of the compound compared to that of hydrocarbons. Heterocyclic compounds are a common class of important compounds in medicinal chemistry and are often used in the synthesis of drugs and other active molecules [1–4]. Many natural products also contain different kinds of heterocyclic structures. The heterocyclic ring of pyrazine (Figure 1) consists of a six-membered aromatic structure containing two nitrogen atoms, arranged in a 1,4 orientation in the carbon skeleton.

The base of pyrazine (pKa 0.65) is weaker than both pyrazine (pKa 2.3) and pyrimidine (pKa 1.3). Pyrazine can be expressed as a resonance hybrid of some typical structures as shown in Figure 1, which has a resonance energy of 24.3 Kcal/mol and a dipole moment of zero due to the symmetry of the pyrazine molecule. The electron density data show that the electron density of nitrogen atoms increases while that of carbon atoms decreases [5]. Pyrazine is widely used in the synthesis of biologically active ingredients and catalysts, which makes pyrazine a hot topic in pharmaceutical chemistry research. In addition, pyrazine compounds include a variety of pharmacological effects, including antipyretic, anti-inflammatory, analgesic, anticancer, antibacterial, and antioxidant activities [6].

Pyrazine derivatives have been extensively studied as a disorder mediator, and Table 1 shows marketed drugs containing pyrazine structures that have been shown to have biological activity relevant to disease treatment. Many phenazine drugs and compounds containing fragments of pyrazine were also reported that have shown potential therapeutic

value, including several that are clinically used to treat human diseases. These results suggest that pyrazine plays an important role in drug discovery [4,7].



**Figure 1.** Structure and pharmacological activity of pyrazine.

**Table 1.** Examples of pyrazine-containing drugs and their pharmacological applications.

Drug	Structure	Biological Activity	Refs.
Acipimox		Hypolipidemic agent	[8]
Amiloride		Potassium sparing diuretic	[9]
Benzamil		Potassium sparing diuretic	[10]
Bortezomib		Proteasome inhibitor	[11–13]
Glipizide		Anti-diabetic agent	[14]
Morinamide		Anti-tubercular agent	[15]

Table 1. Cont.









Drug	Structure	Biological Activity	Refs.
Pyrazinamide		Anti-tubercular agent	[16]
Oltipraz		Schistosomicide and antitumor	[17]
Rimonabant (non-aryl derivative)		Cannabinoid receptor antagonist	[18]
Elpetrigine		Antiepileptic	[19]
Verenicline		Used to treat smoking addiction	[20]
Zibotentan		Anticancer agent	[21]
Amiloride		EnaC blocker	[22]
Paritaprevir		NS3-4A serine protease inhibitor hepatitis C treatment	[23]

Table 1. Cont.








Drug	Structure	Biological Activity	Refs.
Eszopiclone		Insomnia	[24,25]
Zopiclone		Treatment of sleep disorders	[26]
Cephalostatin 1		Anticancer	[27,28]
Favipiravir		Antiviral (approved in Japan, influenza; FDA clearance, COVID-19)	[29–31]
(-)-Barrenazine A		Anticancer	[32]
(-)-Barrenazine B		Anticancer	[32]
Alocasin A		Anticancer	[33]
AKN-028		Acute myeloid leukemia	[34,35]

Table 1. Cont.










Drug	Structure	Biological Activity	Refs.
Botryllazine		Anticancer	[36,37]
Phenazine-1-carboxylic acid		Antibacterial	[38]
2-Bromo-1-hydroxy phenazine		Antibacterial	[39]
Griseolutein A		Antibacterial	[40]
HP-14		Biofilm-eradicating agent	[41]
Iodinin		Antibacterial	[42]
Myxin		Antibacterial	[43]
Quinoxidine		Antibacterial	[44]
Dioxidine		Antibacterial	[44]

Table 1. Cont.

Drug	Structure	Biological Activity	Refs.
NC-190		Anticancer	[45]
NC-182		Anticancer	[46]
Erdafitinib		Anticancer	[47]
Pralatrexate		Anticancer	[48]
Methotrexate		Anticancer	[49]
Selinexor		Anticancer	[50]
Gilteritinib		Anticancer	[51]
Grazoprevir		Anti-hepatitis C virus	[52]

Table 1. Cont.
















Drug	Structure	Biological Activity	Refs.
Telaprevir		Anti-hepatitis C virus	[53]
Triamterene		Potassium-sparing diuretics	[54]
Folic acid		Reduction of the neural tube defect risk	[55]
Selexipag (NS-304)		Pulmonary arterial hypertension	[56]
2-Pyrazinecarboxamide		Antituberculosis	[57]
Thionazine		Insecticide and nematocide	[58]
Tetramethylpyrazine		Anti-inflammatory	[59]
Sulfalen		Urinary tract infection	[60]
Brimonidine		Glaucoma	[61]
Echinomycin		Antibacterial	[62]
Chloroquinoxaline sulfonamide		Anticancer	[63]

Table 1. Cont.

Drug	Structure	Biological Activity	Refs.
Brimondine		Rosacea	[64]
Pyrazine-2-diazo hydroxide		Antitumor	[65]
Acipimox		Hyperlipidaemia	[66]
Sulfalene (sulfamethoxy pyrazine)		Resistant falciparum malaria and antibacterial	[67]
Mirfentanil		Selectivity for the $\mu$ opioid receptor; analgesic	[68]

Here, we review the pharmacological activities and mechanisms of action of natural products containing pyrazine structures. References are available at Web of Science, PubMed, Science Direct, and SciFinder Scholar. In this paper, the biological activities of natural product derivatives containing pyrazines were reviewed and their mechanism of action was also discussed.

## 2. Natural Product–Pyrazine Hybridization


### 2.1. Acrylic and Cinnamic Acid–Pyrazine Hybridization

Hepatitis C virus (HCV) is an RNA virus that is spread primarily through contaminated blood. Beaulieu et al. reported the discovery and optimization of specific allosteric inhibitors of NS5B RNA-dependent RNA polymerase (RdRp) encoded by the HCV virus. Derivative **1** (Figure 2) was obtained by introducing pyrazines into C-2 indole substituents. Compound **1** showed good inhibitory activity against RdRp ( $IC_{50} = 58 \mu M$ ) and good permeability, solubility, and lipophilicity of caco-2 [69].

Rong et al. identified two cinnamate–pyrazine derivatives **2** and **3** with  $IC_{50}$  values of 0.69 and 1.2  $\mu M$  by using HCV NS5B RdRp for compound library screening [70].

RhoA is a member of Rho GTPase, a subgroup of the Ras superfamily of small GTP-binding proteins. RhoA, as an important regulator of various cell signaling pathways, plays an important role in cytoskeletal organization, transcription, and cell cycle progression. RhoA may be a suitable therapeutic target for the treatment of cardiovascular disease. Ma et al. reported on RhoA inhibitors containing cinnamic acid. Compounds **4** and **5** showed high RhoA inhibitory activity with  $IC_{50}$  values of 1.51 and 1.81  $\mu M$  [71].

Deng et al. reported the RhoA inhibitors of cinnamic acid. Compounds **6–9** showed high RhoA inhibitory activity with  $IC_{50}$  values of 1.51, 3.28, 2.58, and 2.62  $\mu M$ . Pharmacological analysis showed that compound **6** had a significant vasodilation effect on PE-induced thoracic aortic ring constriction [72].



**Figure 2.** Cinnamic acid–pyrazine derivatives 1–19.

A series of Pim-2 kinase inhibitors were identified by Qian et al. through high-throughput screening. Compounds **10** and **11** showed stronger inhibition of Pim-2 kinase with IC<sub>50</sub> values of 10 and 12 nM. Compound **11** had a stronger inhibitory effect on Pim-1 kinase with an IC<sub>50</sub> value of 13 nM [73].


Zhang et al. synthesized cinnamic acid–pyrazine derivatives to enhance the bioactivity of cinnamic acid derivatives in neural function and neurovascular protection. The activity of the human microvascular endothelial cell line (HMEC-2) and the human neuroblastoma cell line (SH-SY5Y) against free radical damage increased under the action of compounds **12**–**15**. Compound **15** showed the strongest activity in HBMEC-2 cells with EC<sub>50</sub> values of 3.55 μM, respectively. Compounds **12**–**14** showed the strongest activity in SH-SY5Y cells, with EC<sub>50</sub> values of 3.68, 3.74, and 3.62 μM, respectively [74].

Compounds **16** and **17** showed strong inhibitory activity against cholinesterase (ChE). Compound **16** showed the strongest inhibitory effect on BuChE with an IC<sub>50</sub> of 2.3 nM. Compound **17** had the strongest inhibitory effect on AchE with an IC<sub>50</sub> of 2.6 nM. Unfortunately, compound **17** had weak inhibition on the self-aggregation of Aβ<sub>42</sub> [75].

Wang et al. synthesized a series of ligustrazine–cinnamic acid derivatives as potential neuroprotective agents. Among them, **18** and **19** showed good neuroprotective activity (EC<sub>50</sub> = 5.44 and 3.68 μM). Compound **19** can inhibit the apoptosis of PC12 cells by blocking the mitochondrial apoptosis pathway by up-regulating the ratio of Bcl-2/Bax, down-regulating the expression of cytochrome-C (Cyt-c), and inhibiting the activities of caspase-9 and caspase-3 [76].

Chen et al. synthesized a series of novel ligustrazine acyloxy cinnamic acid derivatives and studied their in vitro inhibitory effect on adenosine diphosphate (ADP)-induced

platelet aggregation and their protective effect on H<sub>2</sub>O<sub>2</sub>-induced oxidative damage of ECV-304 cells. Compounds **20** and **21** (Figure 3) had the highest protective effect on the proliferation of injured ECV-304 cells (EC<sub>50</sub> = 0.046 and 0.020 μM), and compound **22** had the highest antiplatelet aggregant activity (EC<sub>50</sub> = 0.054 μM) [77].



**Figure 3.** Cinnamic acid–pyrazine derivatives 20–33.

Chen et al. evaluated the inhibitory effect of compound **23–25** on ADP-induced platelet aggregation in vitro and investigated the protective effect of H<sub>2</sub>O<sub>2</sub>-induced oxidative damage in Ea.hy926 cells. Compounds **24** and **25** showed the highest protective effect on the proliferation of injured Ea.hy926 cells (EC<sub>50</sub> = 2.2 and 1.7 μM). Compound **23** was the most active antiplatelet aggregator (IC<sub>50</sub> = 9.6 μM) [78].

Chen et al. synthesized a series of ligustrazine–cinnamic acid derivatives based on the structural characteristics of platelet aggregation inhibitor ozagrel. In particular, compounds **26–28** (IC<sub>50</sub> between 57–161 μM) have a higher platelet aggregation activity than ozagrel (IC<sub>50</sub> = 360 μM) [77].

To further investigate the antiplatelet aggregation activity of trimethylpyrazine-2-carboxyloxy-cinnamic acids and esters. Chen et al. designed, synthesized, and evaluated a series of new compounds (**24**, **25**, **29**, and **30**); **25** and **29** were the most effective platelet aggregation inhibitors with IC<sub>50</sub> values of 9.6 and 24.4 μM, respectively, much higher than ozagrel (IC<sub>50</sub> = 144.1 μM). Chen et al. then tested the protective effect of the compound



synthesized its analog **38–40** by substituting the pyrazine ring for trimethoxyphenyl. These compounds improved water solubility and showed potent anticancer activity against the HCT116 cell line with  $IC_{50}$  values of 3.19–8.90  $\mu\text{M}$  [83].

Piperlongumine and ligustrazine have anti-proliferative effects on various types of cancer cells by up-regulating the levels of reactive oxygen species (ROS). Qian et al. designed and synthesized piperlongumine–ligustrazine derivatives and evaluated their bioactivities in vitro and in vivo. Derivative **41** had a more prominent inhibitory effect on the proliferation of drug-sensitive/drug-resistant cancer cells, and the  $IC_{50}$  value was lower than that of piperlongumine. The  $IC_{50}$  value of **41** pairs of resistant BEL-7402/5-FU cells was 0.9  $\mu\text{M}$ , which was about 9 times higher than that of piperlongumine ( $IC_{50} = 8.4 \mu\text{M}$ ). Mechanism studies have shown that derivative **41** regulates the DNA damage protein H2AX and autophagy-related proteins LC3, beclin-1, and p62 in drug-resistant BEL-7402/5-FU cells. TrxR activity was inhibited, ROS levels increased, mitochondrial transmembrane potential decreased, and DNA damage and autophagy were dose dependent. Finally, compound **41** showed strong in vivo antitumor activity at 5 mg/kg, with a tumor inhibition rate of 76% ( $w/w$ ) [84].

Piperlongumine increases the levels of reactive ROS and induces apoptosis in cancer cells by triggering different pathways. However, the poor solubility of Piperlongumine has limited its further research and clinical application. Ligustrazine has a water-soluble pyrazine skeleton, which can inhibit the proliferation and metastasis of cancer cells. The solubility of compounds **42–45** in colorectal cancer HCT116 cells was 8.9–26.2 times higher than that of piperlongumine. Compounds **42–45** showed significant inhibitory effects on U87MG, HCT116, A549, and K562 cell lines with  $IC_{50}$  values ranging from 0.25 to 8.73  $\mu\text{M}$ . Compound **43** also increased ROS levels. Additionally, compound **43** preferentially inhibited the proliferation, migration, invasion, and heteroadhesion of HCT116 cells. Compound **43** inhibits tumor growth and lung metastasis in vivo and prolongs the survival of tumor-bearing mice. Furthermore, compound **43** mitigated TGF- $\beta$ 1-induced epithelial-mesenchymal transformation and Wnt/ $\beta$ catenin activation by inhibiting Akt and GSK-3 $\beta$  phosphorylation in HCT116 cells. Compound **43** has significant anti-proliferation and anti-metastasis activities, which is superior to piperlongumine [85].

## 2.2. Chalcone–Pyrazine Hybridization

Compound **46** (Figure 5) showed good activity against BPH-1 and MCF-7, with  $IC_{50}$  values of 10.4 and 9.1  $\mu\text{M}$ , respectively, comparable to adriamycin ( $IC_{50}$  values of 14.1 and 9.2  $\mu\text{M}$ ). Compound **47** showed the strongest activity against the PC12 cell line with an  $IC_{50}$  value of 16.4  $\mu\text{M}$  [86].

Compound **48** showed the strongest inhibitory effect on the BEL-7402 cell line with an  $IC_{50}$  value of 10.74  $\mu\text{M}$  and no toxicity to HUVEC-12 ( $IC_{50} > 40 \mu\text{M}$ ). Fluorescence staining and flow cytometry analysis showed that compound **48** could induce apoptosis of BEL-7402 cells [87].

Srilaxmi et al. designed and synthesized a series of chalcone–pyrazine derivatives and tested the anticarcinogenic activity of all derivatives against five human cancer cell lines (MCF-7, A549, Colo-205, A2780, and DU-145) using a MTT assay. Compound **49** showed significant inhibitory effects on A549 and Colo-205 cell lines with  $IC_{50}$  values of 0.13 and 0.19  $\mu\text{M}$ . Compound **50** showed a significant inhibitory effect on the MCF-7 cell line with an  $IC_{50}$  value of 0.18  $\mu\text{M}$ . Compound **51** showed significant inhibitory effects on MCF-7, A549, and DU-145 cell lines with  $IC_{50}$  values of 0.012, 0.045, and 0.33  $\mu\text{M}$  [88].

The 50% effective concentration ( $EC_{50}$ ) values of compound **52** against *Xanthomonas axonopodis* pv. Citri (Xac), *Xanthomonas oryzae* pv. oryzae (Xoo), and *Ralstonia solanacearum* (Rs) were 6.72, 15.17, and 9.29  $\mu\text{g}/\text{cm}^3$ , respectively, which were better than those of *Bismertiazol* (44.31, 42.46, and 62.36  $\mu\text{g}/\text{cm}^3$ , respectively) [89].

Compounds **53** and **54** showed good antibacterial activity against *M. luteus*, with a MIC value of 31.25  $\mu\text{g}/\text{mL}$ , similar to that of tetracycline (MIC = 31.25  $\mu\text{g}/\text{mL}$ ) [90].




Figure 5. Chalcone-pyrazine derivatives 46–67.

Luo et al. synthesized a series of ligustrazine–chalcone hybrids and evaluated their antitumor activity *in vitro* and *in vivo*. Compounds **55–60** showed significant cytotoxicity to MDA-MB-231, MCF-7, A549, and HepG-2 cell lines *in vitro*, with  $IC_{50}$  values ranging from 0.99 to 9.99  $\mu\text{M}$ . Compounds **57** and **60** showed significant effects on the MDA-MB-231 cell line ( $IC_{50}$ : **57**, 1.60  $\mu\text{M}$ ; **60**, 1.67  $\mu\text{M}$ ) and MCF-7 cell line ( $IC_{50}$ : **57**, 1.41  $\mu\text{M}$ ; **60**, 1.54  $\mu\text{M}$ ) had a good anti-proliferation effect. Compounds **57** and **60** showed strong inhibition of colony formation in both MDA-MB-231 and MCF-7 cell lines, and also showed strong inhibition of migration of these two cell lines in wound healing tests. It should be noted that compound **57** can significantly induce apoptosis of MDA-MB-231 cells in a concentration-dependent manner, inhibit the transformation of the MDA-MB-231 cell growth cycle, and block the cell growth cycle in the G0/G1 phase. Furthermore, compound **57** showed significant antitumor growth efficacy in *in vivo* anti-proliferation experiments in the NBC model, with a wide safety window. Immunohistochemical analysis showed that compound **57** could significantly reduce the positive rate of Ki-67 in a dose-dependent manner [91].

Wang et al. designed and synthesized six series of ligustrazine–chalcone-modified platinum (IV) complexes and evaluated their anti-proliferation activities. Compounds **61–67** showed significant inhibitory effects on A549, PANC-1, MDA-MB-231, HCT116, and SGC-7901 cell lines, with an  $IC_{50}$  ranging from 0.93 to 7.29  $\mu\text{M}$ . Among them, **66** showed higher cytotoxicity to cancer cell lines than the cisplatin (CDDP) or combination group, and lower cytotoxicity to normal human cells than the CDDP or combination group. Mechanism studies have shown that **66** effectively induces DNA damage and initiates mitochondrial-dependent apoptosis pathways. In addition, **66** regulates the expression level of nuclear factor erythroid 2-related factor 2, glutathione peroxidase 4, and solute carrier family 7 member 11 expression level, significantly induced iron sag. Furthermore, in pancreatic cancer anti-CDDP xenotransplantation models, **66** achieved better antitumor efficiency *in vivo* than CDDP, but without significant side effects [92].


### 2.3. Polyphenols–Pyrazine Hybridization

Du et al. designed and synthesized a series of heterocyclic analogs of resveratrol and evaluated their inhibitory effects on MCF-7 cells. Among them, compound **67** (Figure 6) linked to pyrazine showed a certain inhibitory effect on MCF-7 with an  $IC_{50}$  value of 70.9  $\mu\text{M}$ . The activity exceeded that of resveratrol ( $IC_{50} = 80.0 \mu\text{M}$ ) [93].

Resveratrol is widely used as a vasodilator, free radical scavenger, and antioxidant, as well as an anti-platelet aggregator and anti-atherosclerotic agent for the prevention and treatment of cardiovascular diseases and ischemia [94]. Deng et al. designed and synthesized a series of ligustrazine–stilbene hybrid derivatives. Derivatives **69–72** showed high protective effects on human umbilical cord vascular endothelial cells (HUVECs) damaged by hydrogen peroxide, with values of  $EC_{50}$  ranging from 0.0249 to 28.9  $\mu\text{M}$ . Among them, the  $EC_{50}$  value of compound **71** is 0.0249  $\mu\text{M}$ , which is 30,000 times higher than that of tetramethylpyrazine ( $EC_{50} = 788 \mu\text{M}$ ) [95].

Chen et al. designed and synthesized a series of pyrazole–pyrimidine derivatives, and screened their anti-NO activity and toxicity to normal hepatocytes (L02). Compounds **73** and **74** have low toxicity (against L02:  $IC_{50} = 786.31$  and  $>1000 \mu\text{M}$ , respectively) and strong anti-NO release effect (IR = 68.82%, 63.44%, at 10  $\mu\text{M}$ , respectively) [96].

Liang et al. synthesized the folate receptor (FR)–targeted rhaponticin conjugate FRHA (**75**) using a hydrophilic peptide separator linked to folate and a disulfide linker. FRHA (**75**) maintains a high affinity for FR-positive cells and produces specific dose-responsive activity *in vitro*. Treatment of FRHA (**75**) with a reducing agent shows that the amino reactive derivatives of rhaponticin will be released spontaneously after the reduction of disulfide bonds in the nucleosome. *In vivo*, FRHA (**75**) has also been shown to have specific activity against FR-positive allograft and xenograft models, and possible therapeutic activity leads to mild to moderate toxicity [97].



**Figure 6.** Pyrazine-based resveratrol derivatives, hetero analogs **68–75**, and combretastatin A-4-pyrazine derivative **76–77**.

Nkefang et al. designed and prepared A series of folate–combretastatin A-4 conjugated prodrugs. Prodrugs **76** and **77**, with longer PEG intervals and greater hydrophilicity, enhance the uptake of colon 26 cells by FR-mediated mechanisms and specifically target SC colon 26 tumors in Balb/c mice [93].

Curcumin is a polyphenolic compound extracted from *Curcuma longa*, which has been extensively studied for its potential anticancer effects [98]. Wang et al. synthesized a series of ligustrazine–curcumin derivatives by coupling antitumor bioactive compounds with ether bonds. Among them, compound **78** (Figure 7) pairs BEL-7402, A549, HCT-8, BGC-823, and A2780 cells cell lines were 6.391, 5.890, 7.106, 5.472, and 5.540  $\mu\text{M}$  [99].




Figure 7. Curcumin–pyrazine derivatives 78–87.

Ai et al. designed and synthesized a series of ligustrazine–curcumin hybrids [71]. Compounds **79–81** showed significant inhibitory effects on A549 and A549/DDP cell lines with  $IC_{50}$  ranging from 0.60 to 2.85  $\mu$ M. Pharmacological studies showed that compound **79** inhibited the expression of thioredoxin reductase (TrxR), promoted the accumulation of ROS in cells, and significantly inhibited the apoptosis of proliferation-sensitive (A549, SPCA-1, LTEP-G-2) and drug-resistant (A549/DDP) lung cancer cells. In addition, its antitumor activity was significantly weakened by active oxygen scavenger. In addition, **79** also inhibited NF- $\kappa$ B, AKT, and ERK signaling pathways, P-GP-mediated Rhodamine 123 efflux, P-gp ATPase activity, and P-gp expression in A549/DDP cells [100].

K. Singh et al. synthesized a series of curcumin bioconjugations and tested them for antibacterial and antiviral activity. The antibacterial activity of compounds **82** and **83** against Gram-positive (*S. viridans*) and Gram-negative (*E. coli*, *K. pneumoniae*, and *P. miraleilis*) ranged from 0.09 to 0.54  $\mu$ M [101].

Curcumin, as a cell imaging and photodynamic therapy (PDT) agent, showed significant photocytotoxicity at visible wavelengths of 400–700 nm with  $IC_{50}$  = 8.2  $\mu$ M. Its degradation is prevented by the formation of phototoxic dipyrindophenazine (dppz) complex **84** ( $IC_{50}$  = 3.3  $\mu$ M). However, both compounds are less toxic in the dark ( $IC_{50}$  > 50  $\mu$ M) [102].


Banerjee et al. synthesized a ternary vanadium oxide complex of *O*-phenanthroline with curcumin or disaccharide curcumin, an anticancer compound based on curcumin. Complexes **84** and **85** showed significant phototoxicity at visible light (400–700 nm), with  $IC_{50}$  values < 5  $\mu$ M in HeLa, HaCaT, and MCF-7 cells, and without significant dark toxicity. The DNA ladder, membrane VzFITC/PI, and DCFDA data showed that these complexes lead to apoptotic cell death by forming ROS under light exposure while remaining inert in the dark. Confocal microscopy showed that the complex was mainly located in the cytoplasm, and complex **84** had significant mitochondrial uptake [103].

Banaspati et al. prepared a series of curcumin–nickel (II) complexes and studied their photoinduced anticancer activity in vitro. Curcumin complexes **86** and **87** have REDOX activity in the nickel center, have considerable affinity for binding with calf thymus DNA (ct-DNA), and have moderate affinity for interacting with human serum albumin (HSA). Complexes **86** and **87** exhibit significant photoinduced in vitro cytotoxicity in HeLa and A549 involving reactive ROS with very low dark toxicity. Complexes **86** and **87** are much less toxic to immortalized normal lung epithelial cells (HPL1D). Confocal microscopy images of complexes **86** and **87** show that they are mainly localized in the cytoplasm of A549 cells. JC-1 experiment showed that under visible light irradiation, the sub-G1 cell cycle process of A549 cells was blocked, the mitochondrial membrane potential was significantly lost, and the main mechanism of cell death was apoptosis [104].


#### 2.4. Flavono–Pyrazine Hybridization

Wang et al. designed and synthesized a series of derivatives using ligustrazine and flavonoids as raw materials and tested the antitumor activities of these derivatives. Compounds **88** and **90** (Figure 8) showed the strongest inhibitory effects on HT-29 cell lines, with  $IC_{50}$  values of 10.67 and 10.90  $\mu$ M. Compound **89** showed the strongest inhibitory effect on the MCF-7 cell line with an  $IC_{50}$  value of 10.43  $\mu$ M [87].



Vančo et al. prepared a series of heterologous fish meal containing copper complexes and evaluated their antitumor activity. Complex **91** has significant in vitro cytotoxicity against a variety of human cancer cells (MCF-7, HOS, A549, PC-3, A2780, A2780R, Caco-2, and THP-1) with  $IC_{50}$  values of 2.2–3.3  $\mu$ M. Additionally, complex **91** was less toxic to healthy human hepatocytes, with  $IC_{50}$  > 100  $\mu$ M. Complex **91** is capable of inducing the destruction of intracellular life molecules and subsequent cell death, primarily through the initiation or progression of oxidative stress. Complex **91**, on the other hand, has shown the ability to inhibit inflammation-related signaling pathways (NF- $\kappa$ B/AP-1 activity, NF- $\kappa$ B translocation, and TNF- $\alpha$  secretion) [105].



Comp.	IC <sub>50</sub> (μM)				
	HepG-2	BEL-7402	HT-29	MCF-7	HeLa
Genistein	19.76	34.66	31.13	35.62	34.61
Daidzein	21.81	>40	>40	36.82	>40
<b>88</b>	>40	>40	10.67	>40	>40
<b>89</b>	14.49	28.87	11.72	10.43	14.31
<b>90</b>	>40	25.26	10.90	>40	16.48
Cisplatin	4.14	6.73	5.83	6.75	4.76



Comp.	IC <sub>50</sub> (μM)								
	MCF-7	HOS	A549	PC-3	A2780	A2780R	Caco-2	THP-1	Hep
<b>91</b>	3.0	2.4	3.1	3.3	2.5	2.5	2.6	3.1	>100
Pomiferin	22.0	20.7	21.2	18.5	8.4	8.4	19.8	>10	>50
Cisplatin	30.8	30.0	>80	>80	26.3	26.3	>80	-	>80



Comp. (100 μM)	Hrombin inhibition activity			
	Plasma coagulation parameters			
	TT(s)	APTT(s)	PT(s)	FIB(g/L)
Ethanol (80%)	12.58	19.13	4.32	14.24
Scutellarein	18.12	34.26	5.72	7.41
Tetramethylpyrazine	25.36	39.24	6.13	3.28
<b>93</b>	36.25	48.21	7.72	2.68
<b>94</b>	37.91	47.56	8.57	2.47
<b>95</b>	38.42	49.28	8.32	2.54

Figure 8. Flavono-pyrazine derivatives 88–95.

Poly(ADP-ribose) polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PARP protein. The nerone derivative **92** containing pyrazine showed a significant inhibitory effect on PARP,  $IC_{50} = 77$  nM [106].

Compounds **93–95** showed stronger thrombin inhibitory activity than baicalin and TMP, all of which prolonged TT, APTT, and PT to varying degrees, and significantly reduced plasma FIB content at the same concentration. Compounds **93–95** showed enhanced neuroprotective and antithrombotic activity against  $H_2O_2$ -induced PC12 cell death. Compound **93** was used in cerebral ischemia–reperfusion experiments in the middle cerebral artery occlusion (MCAO) model. The results showed that compound **93** could significantly reduce the infarct size of CA1 pyramidal neurons and reduce the damage to neuron cells. Therefore, compound **93** has obvious antioxidant, anticoagulant, and protective effects on brain I/R injury [107].

### 2.5. Coumarin–Pyrazine Hybridization

The coumarin derivative **96** (Figure 9) containing sulfonamide showed moderate anticancer activity against the breast cancer cell line (T47D) with an  $IC_{50}$  of 86.9  $\mu$ M [108].




Figure 9. Coumarin–pyrazine derivatives **96–105**.

Compound **97** showed significant inhibitory effects in HCT116, C-Raf, and MEK1 cell lines with  $IC_{50}$  values of 0.9, 0.056, and 0.65  $\mu\text{M}$ . The effects of the interaction between the derivative **97** and its on-target and off-target proteins (Raf/MEK, CYPs, and hERG channels) were also detected, but the interaction was weaker [109].

The GI inhibition rate of the coumarin derivative **98** in the MALME-M cell line was 55.75% at a concentration of 10  $\mu\text{M}$  [110].

Compounds **99** and **100** showed high visible-light trigger cytotoxicity against HeLa and MCF-7 cancer cells, producing significantly low micromolar  $IC_{50}$  values ( $IC_{50} = 1.1\text{--}10.0 \mu\text{M}$ ) and much lower toxicity under dark conditions ( $IC_{50} > 50 \mu\text{M}$ ). Confocal microscopy showed that compound **100** accumulated in HeLa cells' mitochondria and induced apoptosis by ROS generation through type 1 photosynthesis [111].

Goel et al. found that arylated imidazo [1,2- $\alpha$ ] pyrazine–coumarin hybrids **101** and **102** exhibited significant antitumor activity at a concentration of 10  $\mu\text{M}$  [112].

H. Halawa et al. synthesized a series of new 4-arylamino-3-nitrocoumarin and evaluated the cytotoxic activity of the KB-3-1 cell line *in vitro* using the resazurin method. Among them, KB-3-1 cells containing the pyrazine derivative **103** showed moderate cytotoxicity with an  $IC_{50}$  value of 43  $\mu\text{M}$  [113].

L. El-Ansary et al. prepared a new Schiff base SCH (**104**) using 8-acetyl-7-hydroxy-4-ethylcoumarin and sulfaclozine as raw materials. Its silver complex SCH-Ag (**105**) was also synthesized. The inhibitory effects of SCH (**104**) and SCH-AG (**105**) on a variety of bacteria and fungi and the antitumor activity against MCF-7 cell lines *in vitro* were evaluated. SCH (**104**) and SCH-AG (**105**) showed strong inhibitory activity against three species of bacteria (*S. aureus*, *B. subtilis*, and *P. aeruginosa*), but no activity against fungi (*A. flavus* and *C. albicans*). Furthermore, the antibacterial activity of SCH-Ag (**105**) was higher than that of SCH (**104**). The  $IC_{50}$  of SCH (**104**) for the MCF-7 cell line was 90.5  $\mu\text{g}/\text{mL}$ , while that of SCH-Ag (**105**) was 9.3  $\mu\text{g}/\text{mL}$ . SCH (**104**) and SCH-Ag (**105**) showed less antitumor activity than cisplatin ( $IC_{50} = 1.7 \mu\text{g}/\text{mL}$ ) [114].

Compound **106** (Figure 10) has good antibacterial activity for strains of *Salmonella typhi* MTCC 537, *Escherichia coli* MTCC 64, and *Candida albicans* MTCC 3017, with a MIC value of 25  $\mu\text{g}/\text{mL}$ . Compound **106** showed obvious inhibitory activity against chitinase with an  $IC_{50}$  value of 7.5  $\mu\text{M}$  [115].

Chai et al. synthesized a series of 7-O-substituted pyridine-4-methyl coumarin derivatives and evaluated their antibacterial activity *in vitro*. Compound **107** showed significant inhibition against *Candida tropicalis*, *Cryptococcus neoformans*, and *Trichophyton rubrum* strains with  $MIC_{80}$  values of 1, 1, and 0.25  $\mu\text{g}/\text{mL}$ . Compound **108** showed obvious inhibition against *Candida tropicalis* strain with  $MIC_{80}$  of 1  $\mu\text{g}/\text{mL}$  [116].

Moosavi-Zare et al. synthesized a series of spiro–pyran derivatives and screened their antioxidant activities by a DPPH radical scavenging assay. Spiropyr derivative **109** showed good dose-dependent (0.2–1  $\text{mg}/\text{mL}$ ) free radical resistance (45.32–55.14%) [117].

Compound **110** showed stronger inhibitory activity against RANKL-induced osteoclast differentiation in RAW264.7 cells at 2  $\mu\text{M}$ , with an inhibition rate of 60.6%. Compound **110** showed no cytotoxicity to the RAW264.7 cell line at a concentration of 10  $\mu\text{M}$  [118].

Compound **111** showed significant protective activity against ECV-304 cells ( $EC_{50} = 0.14 \mu\text{M}$ ), far superior to ligustrazine ( $EC_{50} = 0.60 \mu\text{M}$ ) [119].

Priyanka et al. synthesized a series of 7-benzamidocoumarin derivatives and evaluated *in vitro* the antifilarial activity against the human lymphatic filarial parasite, *Brugia malayi*. There are also pyrazine compounds **112** and **113** with 95% and 70% inhibition of adult motility at 10  $\mu\text{M}$ , which can permanently paralyze the nematode [120].

Ostrowska et al. designed a series of 6-acetyl-7-hydroxy-4-methyl coumarin derivatives containing piperazine groups. Pyrazine-containing derivative **114** showed weak activity against the 5-HT<sub>1A</sub> receptor with a  $K_i$  value of 25 (12.1–51.0) nM [121].

In order to search for potential drugs with good anti-aging effects, Tang et al. synthesized methylrolitin A and its amide derivatives. *Caenorhabditis elegans* (*C. elegans*) was used to evaluate its anti-aging effect and biosafety. Methylrolitin A has good biosafety

for the growth, reproduction, and activity of *C. elegans*. The derivative **115** has the best life-prolonging effect, the anti-aging effect is greater than methylurrolitin A, and it has good biosafety [122].




Figure 10. Coumarin–pyrazine derivatives 106–116.

Urolithin B is a natural metabolite that shows good activity in diseases such as obesity, diabetes, osteoporosis, cancer, learning, and memory disorders. Chen et al. designed and synthesized an amide derivative of urolithin B and verified its anti-aging and biosafety using *C. elegans*. The results showed that **116** had the best anti-aging activity among all derivatives, and the compound had good biosafety [123].


## 2.6. Anthraquinone- and 1,4-Naphthoquinone–Pyrazine Hybridization

The GI<sub>50</sub> of compound **117** (Figure 11) in leukemia cell lines ranged from 0.07–3.65 µM. The GI<sub>50</sub> of the breast cancer subgroups ranged from 0.72–19.1 µM. Compound **117** showed the strongest activity against K562 leukemia, with a GI<sub>50</sub> of 0.07 µM, LC<sub>50</sub>, and TGI of >100 µM, respectively. HL-60 (TB) and MCF-7 cell lines followed, with GI<sub>50</sub> values of 0.68 and 0.72 µM [124].

Compound **118** showed certain antiproliferative activity against MCF-7, HeLa, and A549 (IC<sub>50</sub> = 53.5, 79.1, and 78.3 µM, respectively), and high cytotoxicity against L929 (IC<sub>50</sub> = 49.6 µM) [125].

The derivative of tetramethylpyrazine–rhubaric acid **119** not only inhibited the proliferation of BEL-7402 cancer cells (IC<sub>50</sub> = 26.4 µM), but also significantly inhibited the normal angiogenesis of the chicken chorionic allantoic bladder [126].

The IC<sub>50</sub> of derivative **119** for CHMp (canine inflammatory mammary carcinoma cell line) and MDCK (Madin–Darby immortalized canine kidney cell line) is 42.59 µM and 79.37 µM, respectively. Derivative **119** mediates apoptosis through mitochondrial damage, and arrest of the S phase and G2/M phase by down-regulation of cyclin B1. In addition, derivative **119** reduces filamentous foot and inhibits cell migration by downregulating cadherin. In the CMIC lung metastasis model, derivative **119** can effectively inhibit lung tumor growth without obvious toxicity [127].



**Figure 11.** Anthraquinone–pyrazine derivatives **117–126**.

YM155 (**120**) is a potent broad-spectrum anticancer drug derived from phenotypic screening of inhibitors of survivin expression function. The anticancer drug YM155 (**120**) has been widely studied as a specific statin inhibitor. The IC<sub>50</sub> value of YM155 (**120**) against the H1299 cell line was 0.0137 μM, and the SI value was 18. Furthermore, YM155 (**120**) has been found to induce DNA damage. Si-Han Sherman Ho et al. synthesized a series of YM155 (**120**)-linked pyrazine derivatives and tested their antitumor activity against H1299 cell lines. Compounds **37** and **38** showed little activity against H1299 cell lines, with IC<sub>50</sub> values of 0.0377 and 0.0546 μM, but SI values of **38** and **30** were higher than YM155 (**120**) [128].


Iwai et al. found that YM155 (**120**) down-regulates survivin and exhibits strong antitumor activity. In the Caco-2 cell model, YM155 (**120**) was observed as a substrate for P-gp [99]. Premkumar et al. found that YM155 (**120**) at 25 nM down-regulates survivin in gliomas, down-regulates myeloid cell leukemia sequence 1 (Mcl-1), and up-regulates Noxa levels. These findings suggest that YM155 (**120**) negatively regulates Mcl-1 and survivin through endogenous and exogenous apoptotic pathways and amplifies mitochondrial signaling, thus inhibiting glioma cell resistance to TRAIL-induced apoptosis (TRAIL is a tumor necrosis factor-associated apoptosis-inducing ligand). YM155 (**120**) combined with TRAIL significantly increased antitumor activity and may have application value in the treatment of malignant glioma [129].

Ho et al. evaluated the DNA binding affinity of the test compound (**120–125**) by monitoring the displacement of thiazole oranges from herring sperm DNA [130,131]. The DC<sub>50</sub> of YM155 (**120**) was 20.3 μM and that of adriamycin was 2.64 μM. Compounds **121**, **124**, and **125** showed higher activity than YM155 (**120**), with DC<sub>50</sub> values of 18.4, 12.0, and 15.5 μM, respectively [128].



Glioblastoma (GBM) is the most common primary central nervous system (CNS) malignancy. Furthermore, YM155 (**120**) has clinical tolerance problems due to its lack of cell type selectivity. Thomas J. West et al. synthesized a prodrug of YM155 (**120**), named aYM155 (**121**). aYM155 (**121**) was used against GBM cancer stem-like cells (IC<sub>50</sub> = 0.7–10 nM) from multiple patient sources. The EGFR variant III-expressing (EGFRvIII) cell line (IC<sub>50</sub> = 3.8–36 nM) shows strong cell-killing activity and is activated in a cell type-dependent manner. The survivin inhibitory and apoptosis-inducing activity of YM155 (**120**) is related to its interaction with receptor-interacting protein kinase 2 (RIPK2). In an orthotopic in-

tracranial GBM xenograft model, aYM155 (**121**) significantly inhibited brain tumor growth in vivo, which was related to the pharmacodynamics of selective survivin based on cyto-types [132].


Liu et al. designed and synthesized a series of 1-monosubstituted naphthoquinone imidazole derivatives and tested their antitumor activity in vitro. When the substituent was pyrazine, compound **127** (Figure 12) showed a weak inhibitory effect on MCF-7, HeLa, and A549 cell lines, with IC<sub>50</sub> values ranging from 161–186 μM. However, compound **127** was more toxic to normal cell L929 with IC<sub>50</sub> of 51 μM [133].




Comp.	IC <sub>50</sub> (μM)			
	MCF-7	HeLa	A549	L929
<b>127</b>	161	165	186	51
Doxorubicin hydrochloride	4.6	1.2	8.5	7.5






Comp.	IC <sub>50</sub> (μM)			
	Binding Hsp90	NCI-H460	A431	STO
<b>128</b>	0.68	0.017	0.22	0.052
<b>129</b>	0.51	0.046	0.11	0.042




Comp.	ED <sub>50</sub> (μg/mL)				
	KB/HeLa	SF-268	NCI-H460	RKOp27	RKOp27IND
<b>130</b>	1.368	2.699	1.121	1.194	2.973



Comp.	IC <sub>50</sub> (μM)				
	HCT116	CCRF-CEM	A549	Huh7	DU-145
<b>131</b>	13.15	1.61	8.52	7.33	2.55
Camptothecin	0.009	0.002	0.003	0.006	0.019



Comp.	IC <sub>50</sub> (μM)			
	GLC-82	NCI-H460	MCF-7	MCF-ARD
<b>132</b>	0.92	2.90	8.28	16.46
<b>133</b>	1.78	0.99	12.34	10.26
<b>134</b>	2.26	0.20	4.17	1.88



Comp.	IC <sub>50</sub> (μM)			
	HaCaT		MCF-7	
	Light	Dark	Light	Dark
<b>135</b>	>50	2.57	>50	3.03

Figure 12. Anthraquinone–pyrazine derivatives 127–135.

Bargiotti et al. synthesized a series of 3-arylnaphthalene [2,3] isoxazole-4,9-diones and tested the binding of these compounds to Hsp90 and their effects on Hsp90 client proteins expression in human tumor cell lines. The pyrazine-containing compounds **128** and **129** have a strong affinity for Hsp90 with  $IC_{50}$  values of 0.68 and 0.51  $\mu\text{M}$ . Additionally, compounds **128** and **129** showed significant inhibitory effects on NCI-H460, A431, and STO cell lines, with  $IC_{50}$  values ranging from 0.017 to 0.22  $\mu\text{M}$  [134].

Shanab et al. designed and synthesized a series of azanadione–pyrrolidinated derivatives and evaluated the anti-proliferative activity of all compounds in multiple cell lines. The pyrazine-containing compound **130** showed significant inhibitory activity against KB/HeLa, SF-268, NCI-H460, RKOp27, and RKOp27IND cell lines with  $IC_{50}$  values ranging from 1.121–2.973  $\mu\text{M}$  [135].

Yu et al. designed and synthesized derivatives of indolizinoquinolinedione scaffold and tested the antitumor activity of these compounds. The MTT assay showed that compound **131** containing pyrazine showed significant inhibitory effects on HCT116, CCRF-CEM, A549, Huh7, and DU-145 cell lines, with  $IC_{50}$  values ranging from 1.61 to 13.15  $\mu\text{M}$  [136].

Shen et al. designed and synthesized a series of new Indolizinoquinoxalin-5,12-dione derivatives. Compounds **132–134** showed significant inhibitory effects on the growth of four human tumor cell lines (GLC-82, NCI-H460, MCF-7, and MCF-ARD), with  $IC_{50}$  values ranging from 0.20 to 16.46  $\mu\text{M}$  [137].

Devi et al. synthesized a series of new anthraquinone-based copper (II) complexes. Nuclear targeting complex **135** showed significant cytotoxicity to cancer cells in visible light ( $IC_{50} = 2.57\text{--}3.03 \mu\text{M}$ ), but decreased dark toxicity ( $IC_{50} > 50 \mu\text{M}$ ). Singlet oxygen produced by complex **135** photosensitization is a key cytotoxic substance that causes apoptosis damage in cancer cells. The S-coordination and anthraquinone moiety of complex **135** exhibit double photosensitivity, resulting in a significant PDT effect on cancer cells with minimal dark toxicity [138].

Kim et al. found that tetracyclic heteroquinone analogs containing pyrazine structures were highly cytotoxic to human tumor cell lines. Compound **136** (Figure 13) showed strong inhibitory effects on A549 and XF-498 cell lines with  $IC_{50}$  values of 1.64 and 2.26  $\mu\text{M}$ . Compounds **137–142** showed significant inhibitory effects in A549, SK-OV-3, SK-MEL-2, XF-498, and HCT-15 cell lines, with  $IC_{50}$  values ranging from 0.06–1.01  $\mu\text{M}$ . The  $IC_{50}$  value of compound **142** against the XF-498 cell line was 0.06  $\mu\text{M}$ , 2.6 times that of doxorubicin ( $IC_{50} = 0.16 \mu\text{M}$ ) [139].


Kim et al. designed and synthesized a series of pyrido [3,4-b] phenazinedione derivatives and evaluated their cytotoxic activity and topoisomerase II inhibitory activity. The derivative **143–147** showed significant inhibitory effects on human tumor cell lines (A549, SNU-638, Col2, HT1080, and HL-60), with  $IC_{50}$  values ranging from 0.12 to 1.26  $\mu\text{M}$ . Compound **144** had the strongest effect on the SNU-638 cell line with an  $IC_{50}$  of 0.12  $\mu\text{M}$ . It is 49.75 times that of ellipticine ( $IC_{50} = 5.97 \mu\text{M}$ ). Compounds **143–147** showed inhibitory activity (39–100%) against topoisomerase II at 200  $\mu\text{M}$ . The most active compound was **143**, with an  $IC_{50}$  of 0.082  $\mu\text{M}$  [140].

Lee et al. synthesized a series of benzo[g]quinoxalin-5,10-dione derivatives and evaluated in vitro cytotoxic activity against four human cancer cells (HCT-15, SK-OV-3, MD-MB-468, and T-47D). Compounds **148–155** (Figure 14) showed significant inhibitory activity against four cancer cells with  $IC_{50}$  values ranging from 0.005 to 10  $\mu\text{M}$ . The cytotoxic activity of compound **153** against HCT-15 cells was similar to that of doxorubicin [141].


Kwak et al. synthesized a series of 2-alkyl-2, 3-dihydro-1h-2,6,9-triazacyclopenta[b] anthracene-5,10-diones. The cytotoxic activity of six human cancer cells (HCT-15, SK-OV-3, A549, SNB19, MCF-7, and MCF-7/ADR) was evaluated in vitro. Compounds **156–160** showed significant inhibitory effects on all human cancer cell lines, with  $IC_{50}$  values ranging from 0.035 to 0.381  $\mu\text{M}$  [142].

Lee et al. synthesized pyridazo [2,3-b] phenazine-6,11-dione derivatives and evaluated their cytotoxic activity by the SRB (Sulforhodamine B) assay. Derivatives **161–173** (Figure 15)

showed excellent cytotoxicity to human tumor cell lines (A549, SK-OV-3, SK-MEL-2, XF-498, and HCT-15) with  $IC_{50}$  values ranging from 0.004–0.361  $\mu\text{g}/\text{mL}$ . The killing effect of **161** on HCT-15 ( $ED_{50} = 0.004 \mu\text{g}/\text{mL}$ ) was 23 times that of adriamycin ( $ED_{50} = 0.093 \mu\text{g}/\text{mL}$ ) [143].




Comp.	$IC_{50}$ ( $\mu\text{M}$ )				
	A549	SK-OV-3	SK-MEL-2	XF-498	HCT-15
<b>136</b>	1.64	16.59	16.40	2.26	14.59
<b>137</b>	0.24	1.37	0.68	0.30	0.75
<b>138</b>	0.24	0.89	0.61	0.51	0.20
<b>139</b>	0.42	2.09	0.65	0.85	1.01
<b>140</b>	0.12	0.16	0.21	0.16	0.12
<b>141</b>	0.19	0.29	0.26	0.09	0.13
<b>142</b>	0.13	0.20	0.20	0.06	0.03
Doxorubicin	0.04	0.32	0.05	0.16	0.05



Comp.	$IC_{50}$ ( $\mu\text{M}$ )					Decatenation activity (for Topo II) % inhibition (200 $\mu\text{M}$ )
	A549	SNU-638	Col2	HT1080	HL-60	
<b>143</b>	0.27	1.06	1.26	0.81	0.76	100
<b>144</b>	0.13	0.12	0.55	0.55	0.37	56
<b>145</b>	0.33	0.26	1.05	1.14	1.14	39
<b>146</b>	0.60	0.71	0.50	0.82	>20	46
<b>147</b>	0.15	0.67	0.14	0.50	0.40	74
Ellipticine	2.07	5.97	1.82	5.01	2.60	89

**Figure 13.** Anthraquinone-pyrazine derivatives **136–147**.

Lee et al. designed and synthesized pyridazino [4,5-b]phenazine-5,12-diones. The cytotoxic activity of these compounds against human cancer cell lines was evaluated by a SRB (thiodan B) assay. The cytotoxicity of compound **7a–7j** to cancer cells (A549, SK-OV-3, SK-MEL-2, XF498, and HCT-15) was higher ( $IC_{50} = 0.010–0.195 \mu\text{M}$ ) than that of adriamycin ( $IC_{50} = 0.097–0.225 \mu\text{M}$ ). The most active compounds **179** and **181** are about 10 times more cytotoxic than doxorubicin to all human cancer cell lines [144].



**Figure 14.** Anthraquinone–pyrazine derivatives **148–160**.

Tuyun et al. designed and synthesized a series of benzo[b]phenazine-6,11-dione derivatives and tested their antibacterial and antifungal activities in vitro. Among them, compound **184** (Figure 16) showed the strongest inhibition effect on *S. epidermidis*, and the MIC value was 156.2 μg/mL [145].

Kumar et al. designed and synthesized a series of benzoquinolin-5,10-dione compounds to test for in vitro antituberculosis activity against *M. tuberculosis* H37Rv. Compound **185** is the most active against *M. tuberculosis*, with a MIC of 12.5 μg/mL [146].

Kumar et al. designed and synthesized 2-amino-6-(5,10-dioxo-2,3-diphenyl-5,10-dihydrobenzo[g]quinoxalin-7-yl)-4-(substituted)phenylpyridine-3-carbonitrile. The antibacterial activity of newly synthesized compounds was screened by the L.J. Slope (conventional) method. Compound **186** has the strongest inhibitory effect against *M. tuberculosis* H37Rv with a MIC of 50 μg/mL [147].

Comp.	ED <sub>50</sub> (μg/mL)				
	A549	SK-OV-3	SK-MEL-2	XF 498	HCT-15
<b>161</b>	0.061	0.081	0.019	0.116	0.004
<b>162</b>	0.156	0.097	0.037	0.106	0.005
<b>163</b>	0.167	0.091	0.072	0.106	0.007
<b>164</b>	0.095	0.102	0.031	0.106	0.006
<b>165</b>	0.179	0.131	0.048	0.172	0.008
<b>166</b>	0.128	0.204	0.031	0.172	0.007
<b>167</b>	0.067	0.17	0.042	0.361	0.014
<b>168</b>	0.028	0.007	0.026	0.041	0.027
<b>169</b>	0.047	0.008	0.052	0.037	0.062
<b>170</b>	0.028	0.007	0.039	0.03	0.031
<b>171</b>	0.047	0.061	0.104	0.188	0.062
<b>172</b>	0.033	0.007	0.041	0.071	0.021
<b>173</b>	0.237	0.052	0.052	0.188	0.217
Doxorubicin	0.095	0.16	0.079	0.34	0.093

Comp.	ED <sub>50</sub> (μg/mL)				
	A549	SK-OV-3	SK-MEL-2	XF 498	HCT-15
<b>174</b>	0.174	0.079	0.116	0.116	0.195
<b>175</b>	0.134	0.063	0.085	0.098	0.074
<b>176</b>	0.051	0.031	0.088	0.070	0.024
<b>177</b>	0.029	0.070	0.034	0.021	0.018
<b>178</b>	0.109	0.039	0.029	0.065	0.093
<b>179</b>	0.010	0.034	0.019	0.013	0.012
<b>180</b>	0.053	0.032	0.015	0.029	0.030
<b>181</b>	0.013	0.019	0.012	0.013	0.010
<b>182</b>	0.044	0.070	0.038	0.033	0.026
<b>183</b>	0.138	0.041	0.151	0.118	0.116
Doxorubicin	0.158	0.181	0.097	0.112	0.225

Figure 15. Anthraquinone–pyrazine derivatives 161–183.




																				
<b>184</b> <i>S. epidermidis</i> : MIC = 156.2 μg/mL	<b>185</b> <i>M. tuberculosis</i> : MIC = 12.5 μg/mL																			
																				
<b>186</b> <i>M. tuberculosis</i> H37Rv: MIC = 50 μg/mL	<b>187</b> , R = -OH <b>188</b> , R = -Cl																			
	<table border="1"> <thead> <tr> <th rowspan="2">Comp.</th> <th colspan="3">MIC (μg/mL)</th> </tr> <tr> <th><i>Fusarium solani</i></th> <th><i>Fusarium oxysporum</i></th> <th><i>Aspergillus flavus</i></th> </tr> </thead> <tbody> <tr> <td><b>187</b></td> <td>20</td> <td>20</td> <td>20</td> </tr> <tr> <td><b>188</b></td> <td>20</td> <td>20</td> <td>20</td> </tr> <tr> <td>Bromaniil</td> <td>20</td> <td>20</td> <td>100</td> </tr> </tbody> </table>	Comp.	MIC (μg/mL)			<i>Fusarium solani</i>	<i>Fusarium oxysporum</i>	<i>Aspergillus flavus</i>	<b>187</b>	20	20	20	<b>188</b>	20	20	20	Bromaniil	20	20	100
Comp.	MIC (μg/mL)																			
	<i>Fusarium solani</i>	<i>Fusarium oxysporum</i>	<i>Aspergillus flavus</i>																	
<b>187</b>	20	20	20																	
<b>188</b>	20	20	20																	
Bromaniil	20	20	100																	

Figure 16. Anthraquinone–pyrazine derivatives 184–188.

S. Hammam and others designed and synthesized a series of diarylaminoquinone, and studied the antifungal and antibacterial activities. Among them, compounds **187** and **188** had significant inhibitory effects on *Fusarium solani*, *Fusarium oxysporum*, and *Aspergillus flavus*, with MIC values of 20 µg/mL [148].

Morin et al. synthesized a series of various azotized analogs of 1, 4-naphthoquinone. The inhibitory activity of *P. falciparum* and human glutathione reductases and *P. falciparum* thioredoxin reductase was tested. Compounds 5,8-quinoxalinedione (**189**) and **190** (Figure 17) were the most specific TrxR inhibitors, with a stronger inhibitory effect than menadione [149].




Figure 17. Anthraquinone–pyrazine derivatives **189–210**.

The inhibitory activity of 5,8-quinolinedione (**189**) on the binding of BMAL1/CLOCK to Ebox DNA was concentration dependent, with an  $IC_{50}$  value of approximately 1  $\mu$ M. 5,8-quinolinedione covalently reacts with protein(s) and may regulate dimer formation [150].

Keinan et al. designed and synthesized a series of Cdc25B quinone inhibitors. Among them, WDP1263 (**191**) containing pyrazine is the strongest Cdc25 inhibitor with an  $IC_{50}$  value of 0.5  $\mu$ M, but in the presence of 0.8 mM DTT ( $EC_{50}$  = 1.4  $\mu$ M). WDP1263 (**191**) showed inhibitory activity against the A549 cell line with an  $IC_{50}$  of 22.28  $\mu$ M. WDP1263 (**191**) ( $E_{1/2}$  = 186 mV) prevents the redox cycle through its reducing state [151].

Besset et al. designed and synthesized a heteroquinone compound containing two methoxycarbonyl methyl sulfur groups in the benzoquinone ring and evaluated its Cdc25B phosphatase inhibitory activity. Compound **192** containing pyrazine showed a strong inhibitory effect on Cdc25B with an  $IC_{50}$  value of 5.40  $\mu$ M. Furthermore, derivative **192** inhibited the pancreatic cell line (MiaPaCa-2) by 24% at 100  $\mu$ M [152].

Yang et al. synthesized a series of furanoquinolinedione and isooxazolinequinolinedione derivatives and performed enzyme inhibition tests. Compounds **193** and **194** containing pyrazine have inhibitory activity of TDP2 with  $IC_{50}$  of 32 and 9.3  $\mu$ M [153].


Ryu et al. reported that derivatives of 6-arylamino-quinoxalin-5,8-diones had inhibitory effects on the proliferation of rat aortic smooth muscle cells (RAoSMC). Compounds **195–208** significantly inhibited SMC proliferation, with  $IC_{50}$  values ranging from 1.0–5.5  $\mu$ M. Compounds **196**, **200**, and **201** were the most active with  $IC_{50}$  values of 1.0  $\mu$ M [154].

Chung et al. also reported that the 6-arylamino-quinoxalin-5,8-diones derivatives **195–202** and **209–210** had inhibitory effects on the proliferation of rat aortic smooth muscle cells (RAoSMC). The activity of compounds **195–202** was consistent with the literature. Additionally, compounds **209** and **210** significantly inhibited SMC proliferation with  $IC_{50}$  values of 1.1 and 1.2  $\mu$ M. Furthermore, the inhibitory effect of compound **197** on SMC proliferation is mediated by the regulation of the kinase 1/2 signaling pathway regulated by extracellular signals [155].

Ye et al. synthesized folate-aminocaproate-doxorubicin (FA-AMA-DOX) and performed cytotoxicity and uptake tests on KB, HepG-2, and A549 cell lines. FA-AMA-DOX (**211**) (Figure 18) is more cytotoxic to KB and HepG-2 cells than DOX or AMA-DOX at the same concentration, and FA can reduce cytotoxicity in a dose-dependent manner. On the contrary, FA-AMA-DOX and AMA-DOX showed lower cytotoxicity to A549 cells than DOX at the same concentration, and FA could not reduce cytotoxicity. FA-AMA-DOX (**211**) increased DOX accumulation in KB cells compared to FA-AMA [156].

Huang et al. oxidized the phenol to *O*-naphthoquinone and tested its biological activity. Compound **4h** effectively inhibited the proliferation of different AML (acute myelocytic leukemia) cell lines in vitro, with  $IC_{50}$  values ranging from 0.11 to 0.65  $\mu$ M. In vivo antitumor studies have shown that compound **212** can cause tumor regression in MV4-11 xenograft tumor models at 40 mg/kg/d for 4 h, without obvious toxicity [157].

Sandilya et al. synthesized a series of xanthone derivatives containing 3,6-bis (3'-substituted propoxy) and 3,6-bis (5'-substituted pentyloxy). Anti-inflammation of Wistar albino rats was studied by carrageene-induced metatarsal edema in rats. Compounds **213** and **214** at 200 mg/kg body weight showed a slightly lower inhibitory effect than diclofenac sodium (10 mg/kg body weight dose, inhibition effect: 68.27%) in plantar edema after 6 h, with an inhibition effect of 63.32% and 62.75%, respectively [158].



**Figure 18.** Structure of FA-AMA-DOX (**211**), O-naphthoquinone **212**, and xanthone derivatives **213–214**.

### 2.7. Lignin–Pyrazine Hybridization

According to Zhao et al., 4'-demethylepipodophyllotoxin (DMEP) was prepared by a series of new types of podophyllum topoisomerase II (Topo II) inhibitors. The antitumor activity of compound **215** (Figure 19) against the tumor cell lines HeLa, A549, HepG-2, and BGC-823 was significantly improved with IC<sub>50</sub> values of 0.88, 3.83, 1.21, and 4.15 μM, respectively. More than 4'-demethylepipodophyllotoxin antitumor activity (the IC<sub>50</sub> values of HeLa: 15.96 μM; HepG-2: 18.74 μM; A549: 52.08 μM; and BGC-823: 21.26 μM). The antitumor activity of compound **216** against BGC-823 was significantly improved with an IC<sub>50</sub> value of 1.50 μM. The amide derivatives **217** and **218** showed strong inhibitory effects in HepG-2, HeLa, A549, and BGC-823 cell lines, with IC<sub>50</sub> values ranging from 3.49 to 18.71 μM. Compound **217** had the strongest killing ability against the BGC-823 cell line with an IC<sub>50</sub> value of 3.49 μM. Compound **215** inhibited the G2/M cycle of HeLa cells and induced apoptosis by strongly attenuating Topo II DNA unshackling relaxations [159].

Wu et al. synthesized a series of podophyllotoxin (PPT) derivatives and evaluated the cytotoxicity of A549, MCF-7, HepG-2, and L02 cells. The IC<sub>50</sub> values of compound **219** containing pyrazine for A549 and HepG-2 cell lines were 9.3 and 11.7 μM. The IC<sub>50</sub> values of compound **220** against the A549 and MCF-7 cell lines were 8.1 and 11.3 μM [160].

Zhang et al. synthesized a series of poxylotoxin aromatic heterocyclic esters and evaluated the anticancer effects of two human chronic myeloid leukemia cell lines (K562

and K562/ADR). The IC<sub>50</sub> values of compound **221** containing pyrazine for the K562 and K562/ADR cell lines were 0.034 and 0.022 μM [161].





Figure 19. Lignin-pyrazine derivatives **215–226**.

Li et al. designed and synthesized podophyllotoxin derivatives and evaluated their anticancer activity in vitro against several human cancers. The pyrazinyl derivative **222** inhibited the HL60, SGC-7901, and A549 cell lines with IC<sub>50</sub> values of 6.71, 12.72, and 11.15  $\mu$ M [162].

Castro et al. designed and synthesized podophyllotoxin e-ring-modified derivatives and evaluated their cytotoxicity. The IC<sub>50</sub> value of compound **223–226** containing pyrazine against the P-388, A549, HT-29, and MEL-28 cell lines was 0.56–2.8  $\mu$ M, and the antitumor activity of compound **223–226** was lower than that of podophyllotoxin (IC<sub>50</sub> = 0.012  $\mu$ M) [163].

Compounds **227–230** (Figure 20) had a corrected mortality rate of 51.7%, 51.7%, 55.2%, and 55.2% in vivo against *Mythimna separata* (*M. separata*) at 1 mg/mL, higher than or equivalent to the activity of Toosendanin (51.7%) [164].



**Figure 20.** Lignin–pyrazine derivatives **227–239**.

Zhi et al. conducted an in vivo insecticidal activity test on the pre-third-instar larva of *M. separata* (Walker) at 1 mg/mL. Compounds **231** and **232** exhibited the best potent insecticidal activity with the final mortality rate of 53.3% and 63.3%, the activity was higher than Toosendanin (46.7%) [165].

Zhi et al. synthesized C-ring, D-ring, and E-ring modified phenazines oxime derivatives of podophyllotoxin and performed 1 mg/mL in vivo insecticide on the pre-third-instar larva of the oriental armyworm *M. separata* (Walker). Compounds **233–235** exhibited the best potent insecticidal activity with a final mortality rate of 51.7%, 62.1%, and 58.6%, the activity was higher than Toosendanin (48.3%) [166].


In vivo insecticidal activity against the pre-third instar larva of *M. separata* (Walker) was measured at 1 mg/mL. Derivatives **236–238** exhibited the most promising insecticidal activity with the final mortality rate of 62.1, 62.1%, and 72.4%, The activity was higher than toosendanin (48.3%). Depending on the symptoms of *M. separata* tested, the derivative **238** May shows anti-melting hormone effects [167].

Hou et al. connected methotrexate (MTX) with the hydrophobic drug podophyllotoxin (PPT) via a disulfide bond to obtain the amphiphilic drug–drug coupling prodrug (MTX-SS-PPT). The first two parent molecules of the drug self-assemble into stable nanoaggregates (NAs) in an aqueous solution, which realizes the self-delivery of the drug. Additionally,

the presence of disulfide bonds in MTX-SS-PPT (**239**) can be controlled by using high concentrations of dithiothreitol (DTT). Intracellular mercaptan breaks disulfide bonds in MTX-SS-PPT (**239**), releasing drugs and killing tumor cells. Methotrexate-covered NAs can also target folate receptor-positive KB cells. Animal experiments have shown that methotrexate-covered NAs prodrug has good blood compatibility, and MTX-SS-PPT (**239**) NAs can reduce the size of xenograft tumors with few side effects [168].

## 2.8. Steroidal–Pyrazine Hybridization

Amelie Talbot et al. designed and synthesized acetyne-based steroid derivatives **240** and **241** (Figure 21) and evaluated the antitumor activity of these two compounds. The inhibition rates of compounds **240** and **241** reached 98% and 97% at the concentration of 10  $\mu\text{M}$ . The inhibition rates of Jurkat cells reached 93% and 91% at the same concentration [169].



**Figure 21.** Steroidal–pyrazine derivatives **240–247**.

Compounds **242** and **243** showed significant inhibitory effects on PC-3 cell lines, with IC<sub>50</sub> values of 6.88 and 0.93  $\mu\text{M}$ . THLE-2 cells of compound **243** showed low cytotoxicity (IC<sub>50</sub> = 26.70  $\mu\text{M}$ , SI = 28.71). Compound **243** induced apoptosis of PC-3 cells in a dose-dependent manner and led to cell cycle stagnation in the G2/M phase [170].

Tao et al. reported the synthesis and antitumor activity of DHEA derived from C-16 ropyrrolidine. Compounds **244** and **245** showed the best activity with LC<sub>50</sub> values less than 6.19 and 9.92  $\mu\text{g/mL}$ , exceeding dehydroepiandrosterone activity (LC<sub>50</sub> > 200  $\mu\text{g/mL}$ ) by using the brine shrimp test [171].

The D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivative **246** showed moderate inhibitory activity in T-47D cells with an IC<sub>50</sub> value of 3.04  $\mu\text{M}$ . Compound **246** was not as active as dehydroepiandrosterone (IC<sub>50</sub> = 2.55  $\mu\text{M}$ ) [172].

Steroidal C-17 pyrazine (**247**) showed moderate inhibitory activity against PC3-AR cell lines with  $IC_{50}$  of 366 nM. Compound **247** is also a potent CYP17 inhibitor with an  $IC_{50}$  value of 3.81  $\mu$ M for CYP17 [173].

The 16-position aryl or heteraryl side chain of estrone is a potent inhibitor of  $17\beta$ -HSD1. Among them, compound **248** (Figure 22) containing the pyrazine group showed an inhibitory effect on  $17\beta$ -HSD1 with an  $IC_{50}$  value of 3.62  $\mu$ M [174].




Figure 22. Steroidal–pyrazine derivatives 248–256.

Ivanov et al. prepared a series of estrone-derived quinolines. Acetylenated estrone and its derivatives have significant biological activity as alkaline phosphatase inhibitors. Compounds **249**, **250**, and **252** were more potent TNAP inhibitors with  $IC_{50}$  values of 0.52, 0.48, and 0.25  $\mu$ M, exceeding the activity of Levamisole ( $IC_{50}$  = 19.21  $\mu$ M). Compounds **249**, **251**, and **252** are potent IAP inhibitors with  $IC_{50}$  values of 0.32, 0.92, and 0.44  $\mu$ M, which exceeds the activity of L-phenylalanine ( $IC_{50}$  = 80.21  $\mu$ M) [175].

Benoît et al. synthesized bimetallic Au(III)/Au(I) complexes with 17 $\alpha$ -ethylestradiol as the carrier. The toxicity of estradiol-conjugated AuC6Estra (**253**) to estrogen receptor-positive (ER+) cancer cells was greater than that of ER-cancer cells and non-cancer cells. AuC6Estra (**253**) tested MCF-7 (ER+), MDAMB-231 (ER-), and MRC-5 (healthy fibroblasts) cells. The anti-proliferation effect of AuC6Estra (**253**) on ER+ cells was slightly higher than that in ER- and non-cancer cells [176].

Ananthan et al. synthesized a series of estrogen-functionalized copper complexes and studied them as electrochemically active DNA binding and splitting agents. The cytotoxic activity of these compounds was evaluated against estrogen receptor-positive (ER+) and negative (ER-) human cancer cell lines, and compounds **254–256** showed inhibitory effects against A2780, 2008, A431, MCF-7, and HCT-15 cell lines with IC<sub>50</sub> values ranging from 0.04–2.00  $\mu$ M. Complex **256** has a high intercalation interaction with nuclear DNA in vitro and is a strong DNA-cutting agent. Finally, complex **256** is involved in cellular redox stress by stimulating ROS production [177].

The steroid–pyrazine derivative **257–260** (Figure 23) showed significant antibacterial activity against two Gram-positive bacteria and two Gram-negative bacteria. The MIC value of compound **257** against the *E. coli* strain was 0.39  $\mu$ M. The MIC value of compound **258** against the *S. typhimurium* and *E. coli* strains was 0.39  $\mu$ M. The MIC value of compound **259** against the *S. pyogenes* strain was 0.39  $\mu$ M. The MIC value of compound **260** against the *B. aureus*, *S. typhimurium*, and *E. coli* strains was 0.39  $\mu$ M. The antibacterial activity of compound **257–260** was higher than that of the standard drug amoxicillin (MIC = 3.12  $\mu$ M) [178].





Figure 23. Steroidal–pyrazine derivatives **257–264**.

Salman Ahmad Khan et al. found that the MIC values of compounds **261** and **262** against *E. coli* strains were 64 and 32 mg/mL, higher than the activity of cholesterol (MIC = 512 mg/mL). It was comparable to positive control chloramphenicol (MIC = 32 mg/mL) [179].

Khan et al. found that compounds **263** and **264** had significant antibacterial activity against two Gram-positive and two Gram-negative bacteria. The MIC values of compound **263** for *S. aureus*, *S. pyogenes*, *S. typhimurium*, and *E. coli* strains were 0.78, 0.78, 0.78, and 0.39 mg/mL. The MIC values of compound **264** were 0.78, 0.78, 0.39, and 0.39 mg/mL [180].

Compound **265** (Figure 24) showed moderate inhibitory activity against H37RvMa in MB7H9/ADC medium with a MIC<sub>90</sub> value of 17.49 μM and low toxicity to CHO cells (IC<sub>50</sub> > 50 μM) [181].



**Figure 24.** Steroidal-pyrazine derivatives **265–269**.


Stephen Barrett et al. used planephroline-modified aromatic ligands and copper (II) complexes of steroids (ethinynoestradiol and ethyl ketone) and screened these compounds for antimicrobial resistance against *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* (MRSA). Testosterone derivative **266** showed the strongest inhibitory effect on *S. aureus*, with a MIC<sub>50</sub> of 1.5 μM. Estradiol derivative **267** showed the strongest inhibitory effect on MRSA, with a MIC<sub>50</sub> of 17.5 μM [182].

Wang et al. synthesized the gaudatin–pyrazine derivative **268** and evaluated its anti-hepatitis B virus (HBV) activity in HepG-2 cells. Compound **268** not only inhibited the secretion of HBsAg ( $IC_{50} = 95.52 \mu\text{M}$ ) and HBeAg ( $IC_{50} < 50.28 \mu\text{M}$ ), but also inhibited the replication of HBV DNA ( $IC_{50} = 47.92 \mu\text{M}$ ). Compound **268** showed low toxicity to HepG-2 cells, with a value of  $CC_{50}$  of  $61.34 \mu\text{M}$  [183].

Compound **269** showed a neuroprotective effect on  $\text{H}_2\text{O}_2$ -induced SH-SY5Y cells, with a cell protective activity of 22.3% at  $10 \mu\text{M}$ , more than diosgenin activity (6.7%) [184].

### 2.9. Terpene–Pyrazine Hybridization

Betulinic acid-linked ligustrazine derivative **270** (Figure 25) showed good antitumor activity, with  $IC_{50}$  values of 4.19, 5.23, 4.48, 4.23, and  $4.34 \mu\text{M}$  against BEL-7402, HT-29, HepG-2, MCF-7, and HeLa cells. The cytotoxicity selective assay showed that **270** had low cytotoxicity to MDCK cells ( $IC_{50} > 20 \mu\text{M}$ ). Fluorescence staining and flow cytometry analysis showed that **270** could induce HepG-2 cell apoptosis. Further studies showed that **270**-induced apoptosis was mediated by depolarizing mitochondrial membrane potential and increasing intracellular free  $\text{Ca}^{2+}$  concentration [185].



**Figure 25.** Betulinic acid–pyrazine derivatives **270–274**.

The  $IC_{50}$  values of compound **271** against the BEL-7402, HepG-2, and HeLa cell lines were 4.065, 8.475, and  $4.419 \mu\text{M}$  [186].

Xu et al. designed and synthesized a series of betulinic acid-linked ligustrazine derivatives, and screened their selective cytotoxic activity against five cancer cell lines (HepG-2, HT-29, HeLa, BCG-823, and A549) and nonmalignant cell lines MDCK using a standard MTT assay. Compounds **272** and **273** showed the strongest inhibitory effect on the BGC-823 cell line, with  $IC_{50}$  values of 0.84 and  $1.49 \mu\text{M}$ . Compound **274** showed the highest cytotoxic activity against tumor cell lines (mean  $IC_{50} = 2.31 \mu\text{M}$ ), and the strongest cytotoxic activity against HT-29 and HeLa with  $IC_{50}$  values of 1.70 and  $1.74 \mu\text{M}$ . Further mechanism studies showed that **274**-induced apoptosis was associated with the loss of mitochondrial membrane potential and increased intracellular free  $\text{Ca}^{2+}$  concentration [187].

The betulinic acid derivative **275** (Figure 26) inhibited the osteoclast differentiation of RAW.264.7 cells induced by RANKL, and the inhibitory rate reached 100% at  $5 \mu\text{M}$ . The activity of betulinic acid was higher than that of betulinic acid ( $5 \mu\text{M}$ : 0%). Compound **275** still had a certain inhibitory effect at a concentration of  $1.0 \mu\text{M}$ , and the inhibitory rate was 14.5% [188].




Figure 26. Betulinic acid–pyrazine derivatives 275–286.

Compound 276 showed an obvious inhibitory effect in the A549 cell line with an IC<sub>50</sub> value of 0.25  $\mu$ M. Compound 277 showed the strongest inhibitory effect on HT-29, K562, K562-TAX, and B2-4 cell lines with IC<sub>50</sub> values of 2, 0.4, 4, and 0.3  $\mu$ M [189].

Haavikko et al. determined the leishmania activity of compound 276 using the alamar-Blue aseptic flagellate activity assay against leishmania donovani. Compound 276 showed an obvious inhibitory effect on leishmania donovani with an IC<sub>50</sub> value of 13.2  $\mu$ M [190].

The betulinic acid derivatives 276, 278, and 279 showed significant inhibitory effects on two cancer cells (CCRF-CEM and HCT116). The IC<sub>50</sub> values of compound 276 against CCRF-CEM and HCT116 cell lines were 0.5 and 11.06  $\mu$ M. The IC<sub>50</sub> values of compound 278 against the CCRF-CEM and HCT116 cell lines were 12.25 and 20.5  $\mu$ M. The IC<sub>50</sub> values of compound 279 against CCRF-CEM and HCT116 cell lines were 5.87 and 18.01  $\mu$ M [191].

Hodon et al. synthesized a series of betulinic acid–pyrazine compounds and tested the cytotoxicity of these compounds in multiple cancer cell lines. Compounds (276–277 and 280–284) were preferentially and highly cytotoxic to leukemia cell lines (CCRF-CEM, K562, CEM-DNR, and K562-TAX) (IC<sub>50</sub> between 0.43 and 18  $\mu$ M). Compound 283 showed a significant inhibitory effect in CIM-DNR cells with IC<sub>50</sub> of 0.49  $\mu$ M. The IC<sub>50</sub> activity of compound 284 against K562 cells was 0.026  $\mu$ M. In addition, compounds 276, 280, and 282 inhibited the growth and degradation of HCT116 and HeLa cells in sphere cultures [192].

Compounds 285 and 286 have an obvious inhibition effect on 4T1 and MIA-PaCa-2 cell lines. The IC<sub>50</sub> value of compounds 285 and 286 against 4T1 cell lines was 2.88  $\mu$ M, which exceeded the activity of betulinic acid (IC<sub>50</sub> = 6.29  $\mu$ M). The IC<sub>50</sub> values of MIA-PaCa-2 cell lines were 3.87 and 4.36  $\mu$ M, which exceeded the activity of betulinic acid (IC<sub>50</sub> = 25.63  $\mu$ M) [193].

Pyrazine-thickened 23-hydroxyl betulinic acid, further modified by replacing C-28 carboxyl with ester and amide bonds, increased its antitumor activity. Compound **109** (Figure 27) showed the strongest activity against the cell lines SF-763, B16, and HeLa, with  $IC_{50}$  values of 3.53, 4.42, and 5.13  $\mu\text{M}$ , respectively. In a preliminary mechanism study, **109** induced G1 phase cell arrest and significantly induced apoptosis of B16 cells in a dose-dependent manner. Furthermore, the *in vivo* antitumor activity of **109** was demonstrated in mice with H22 liver cancer and B16 melanoma (tumor inhibition rates were 55.6% and 62.7%, respectively) [194].




Figure 27. A 23-hydroxyl betulinic acid–pyrazine derivative **287**.

Compound **288** (Figure 28) showed moderate antitumor activity, with  $GI_{50}$  values of 32.6  $\mu\text{g}/\text{mL}$  for IMR 32 (neuroblastoma) cell lines [195].




Figure 28. Lupeol–pyrazine derivatives **288–289** and betulin–pyrazine derivatives **290–291**.

Betulinic acid–pyrazine derivative **289** showed significant anti-proliferation activity against HeLa and HepG-2 cell lines with  $IC_{50}$  values of 42 and 19  $\mu\text{M}$  [196].

Bhandari et al. synthesized the pyrazine derivative **289** from lupinol and evaluated its anti-inflammatory activity by inhibiting NO production in LPS-induced RAW264.7 and J774A.1 cells. The  $IC_{50}$  of compound **289** inhibited NO production in RAW264.7 and J774A.1 cells was 32.4  $\mu\text{M}$  [197].

The cytotoxicity of compound **290** in cancer cells (mean  $IC_{50}$  = 4.86  $\mu\text{M}$ ) was three times higher than that of normal cells (mean  $IC_{50}$  = 16.11  $\mu\text{M}$ ). The  $IC_{50}$  values of compound **290** against the HeLa, HepG-2, BGC-823, and HT-29 cell lines were 4.91, 4.07, 4.24, and 6.21  $\mu\text{M}$ . Additionally, **290** was more cytotoxic to tumor cells than the positive drug cisplatin. Furthermore, **290** was more cytotoxic to tumor cells than its lead compound TB (**291**) and positive control cisplatin. Subsequently, fluorescence staining, apoptosis detection, and cell cycle analysis showed that **290** induced early apoptosis of HepG-2 cells and blocked the G1 phase cell cycle [198].

The antitumor component ligustrazine was combined with oleanolic acid to form TOA (**292**) (Figure 29). TOA showed a good anticancer effect in vitro [79], with  $IC_{50}$  values of 21.45 and 8.683  $\mu\text{M}$  for HepG-2 and HeLa cell lines [199]. The  $IC_{50}$  values of the BEL-7402, HepG-2, HT-29, and HeLa cell lines were 6.359, 23.75, 8.339, and 23.77  $\mu\text{M}$  [186].




Figure 29. Oleanolic acid–pyrazine derivatives **292**–**296**.

TOA (**292**) blocks the expression of the nuclear transcription factors NF- $\kappa$ B/p65 and COX-2 in S180 mice [200]. Furthermore, acute toxicity tests confirmed that the  $LD_{50}$  of TOA (**292**) exceeded 6.0 g/kg by intragastric administration in mice. However, the poor hydrophilicity of TOA (**292**) limits its oral bioavailability [200].


Compound **293** showed good antitumor activity, with an  $IC_{50}$  value of 4.273  $\mu\text{M}$  against the BEL-7402 cell line [186].

Ursolic acid-linked ligustrazine derivative **294** showed good antitumor activity, with  $IC_{50}$  values of 9.28, 8.43, 7.94, 5.69, and 4.37  $\mu\text{M}$  for BEL-7402, HT-29, HepG-2, MCF-7, and HeLa cells. The cytotoxicity selective assay showed that **294** had low cytotoxicity to MDCK cells ( $IC_{50}$  = 16.39  $\mu\text{M}$ ) [185].

Chu et al. linked amino acids to TOA (**292**) via ester bonds and evaluated their cytotoxicity in four cancer cell lines (HepG-2, HT-29, HeLa, and BGC-823) using a standard MTT assay. Compounds **295** and **296** not only showed good cytotoxicity ( $IC_{50}$  < 3.5  $\mu\text{M}$ ), but also showed better hydrophilicity than TOA (**292**). Compound **295** showed the strongest inhibitory effect on the HepG-2 cell line with an  $IC_{50}$  value of 1.999  $\mu\text{M}$ . Compound **296** showed the strongest inhibitory effect on HT-29, HeLa, and BGC-823 cell lines with  $IC_{50}$  values of 2.347, 2.383, and 2.481  $\mu\text{M}$ . Furthermore, the nephrotoxicity of 6a ( $IC_{50}$  = 4.884  $\mu\text{M}$ )

to MDCK cells was lower than that of **296** ( $IC_{50} = 2.310 \mu\text{M}$ ) and cisplatin ( $IC_{50} = 3.691 \mu\text{M}$ ). Combination **296** can induce HepG-2 apoptosis through nuclear division and has low nephrotoxicity [199].

A series of hawthorn acid derivatives were synthesized by introducing various thickened heterocycles at C-2 and C-3. Their inhibitory effects on PTP1B, TCPTP, and related PTPs were evaluated. Compounds **297–299** (Figure 30) showed significant increases in inhibitory power and selectivity, and the three most potent PTP1B inhibitors, **297** ( $IC_{50} = 1.43 \mu\text{M}$ ), **298** ( $IC_{50} = 1.79 \mu\text{M}$ ), and **299** ( $IC_{50} = 1.78 \mu\text{M}$ ), were shown to be about two times stronger than hawthorn acid. Furthermore, **297–299** are 4.1, 4.6, and 3.1 times more selective for PTP1B than for TCPTP [201].



**Figure 30.** Oleanolic acid–pyrazine derivatives **297–309**.

Oleanolic acid has been found to have an anti-bone resorption effect. The oleanolic acid derivative **300** inhibited the formation of osteoclast-like multinucleated cells (OCL) and showed quite strong activity even at 200 nM. The formation of oleanolic acid was only 34.1% compared to the control group (100.0%) [202].


Compound **301** is a novel molecule with a strong anti-osteoporosis effect in vivo. To study the molecular mechanism of **301**, a novel fluorescent-labeled chemical probe with biological activity was designed and synthesized. Compared to **302**, fluorescence compounds **303** and **304** showed a stronger inhibitory activity against RANKL-induced osteoclast differentiation in RAW264.7 cells at 2  $\mu\text{M}$ , with an inhibition rate of 95.0% and 87.8%. Compounds **303** and **304** did not show cytotoxicity for the RAW264.7 cell line at a concentration of 10  $\mu\text{M}$  [118].

The inhibitory activity of pyrazine-fused oleanolic acid derivatives on osteoclast formation induced by the nuclear factor- $\kappa\text{B}$  ligand receptor activator (RANKL) was evaluated using a cell-based tartrate-resistant acid phosphatase (TRAP) assay. The most potent compound **305** had an  $IC_{50}$  of 62.4 nM, and cytotoxicity in marine-derived bone monocytes/macrophages (BMDMs) indicated that inhibition of **305** in osteoclast differentiation was not due to its cytotoxicity. More importantly, **305** mitigated bone loss in bilateral ovariectomy mice, and preliminary mechanism studies showed that **305** affected the early stages of osteoclast genesis [203]. Furthermore, compounds **305–308** showed considerable

inhibitory activity, inhibiting osteoclast formation by more than 80% at lower concentrations (0.5  $\mu\text{M}$ ) compared to the control group.

The results of  $\alpha$ -glucosidase inhibitory activity in vitro showed that compound **309** showed certain inhibitory activity with  $\text{IC}_{50}$  values of 3.14  $\mu\text{M}$ , respectively. However, the activity was inferior to oleanolic acid ( $\text{IC}_{50} = 2.41 \mu\text{M}$ ) [204].

Derivative **310** (Figure 31) is a hederagenin derivative that binds to paclitaxel at 10  $\mu\text{M}$  with an  $\text{IC}_{50}$  value of 2.4 nM against drug-resistant KBV cells. Derivative **310** can activate P-gp ATPase, resulting in the inability of drug-resistant cells to remove the drug from the body. Therefore, the derivative **310** can enhance the antitumor activity of paclitaxel in KBV cells, and the reversal effect of the drug is stronger than that of verapamil ( $\text{IC}_{50} = 4.9 \text{ nM}$ ). Furthermore, in vivo experiments showed that under combined use of paclitaxel (30 mg/kg) and derivative **310** (10 mg/kg), the body weight of nude xenograft mice decreased slightly, and tumor weight decreased to 41.88%. The results showed that derivative **310** reversed multidrug resistance by stimulating the ATPase activity of P-gp and then competing with chemotherapeutic drugs for binding to P-gp, but was less soluble due to the benzyl group at C-28 [205].



**Figure 31.** Hederagenin–pyrazine derivatives **310–314**.

The cell assay showed that derivative **311** had the strongest antitumor reversion activity. When the derivative **311** (10  $\mu\text{M}$ ) was combined with paclitaxel (100 nM), the survival rate of the KBV cells reached 18.60%, surpassing that of compound **310** (19.64%) and hederagenin (149.47%) [206].

Compound **312** at 5  $\mu\text{M}$  significantly improved the cytotoxicity of paclitaxel in resistant KBV cells and sensitized cells to paclitaxel, thus preventing cells from entering the G2/M phase and inducing apoptosis. Compound **312** may block the efflux of P-gp drugs by stimulating the activity of P-gp ATPase. In vivo experiments demonstrated that compound **312** increased the efficacy of paclitaxel in KBV cancer cell-derived xenograft tumors [207].

In order to improve the water solubility and tumor multidrug resistance reversal activity of **309**, Wang et al. designed and synthesized a new series of hederagenin derivatives. These derivatives significantly reversed the multidrug resistance phenotype of KBV cells to paclitaxel at a concentration of 10  $\mu\text{M}$ . The water solubility of PEGylated derivatives **313** increased approximately 20 fold compared to **310**, while maintaining tumor multidrug resistance reversal activity. Therefore, pegylation is an effective method to improve water solubility while maintaining tumor multidrug resistance reversal activity [208]. Compound **313**, the most active compound in vitro, showed good chemical stability to esterases within 24 h and increased the sensitivity of KBV cells to paclitaxel and vincristine with  $\text{IC}_{50}$  values of 4.58 and 0.79 nM, respectively. Compound **313** also increased the sensitivity of MCF-7T cells to paclitaxel and vincristine with  $\text{IC}_{50}$  values of 0.89 and 0.04 nM, respectively. The combination of compound **313** and paclitaxel significantly increased the apoptosis rate of KBV cells. Compound **313** treatment increased the accumulation of rhodamine 123 and Flutax1 in KBV and MCF-7T cells at 5 and 10  $\mu\text{M}$  concentrations, suggesting that compound **313** played a role in reversing tumor resistance by effectively inhibiting the efflux function of P-gp [208].

Fang et al. designed and synthesized a series of hederagenin–pyrazine derivatives and screened the in vitro cytotoxicity of five tumor cell lines. The antitumor activity of compound **314** against A549 ( $\text{IC}_{50} = 3.45 \mu\text{M}$ ) was comparable to that of cisplatin ( $\text{IC}_{50} = 3.85 \mu\text{M}$ ). Compound **314** induced early apoptosis of A549 cells in a concentration-dependent manner and induced cell arrest in the S phase [209].

The results of  $\alpha$ -glucosidase inhibitory activity in vitro showed that compound **315** (Figure 32) showed certain inhibitory activity with  $\text{IC}_{50}$  values of 7.84  $\mu\text{M}$ , respectively. However, the activity was less than 3-carbonyl ursolic acid ( $\text{IC}_{50} = 2.47 \mu\text{M}$ ) [210].


Tryptophan hydroxylase 1 (Tph-1) is the main enzyme in the biosynthesis of peripheral blood albumin, providing a new target for the design of anabolic agents for osteoporosis. Fu et al. synthesized a series of ursolic acid derivatives and bioevaluated them using RBL2H3 cells and ovariectomized rats. Among these compounds, compound **316** showed effective inhibitory activity against serotonin biosynthesis. Further studies showed that **316**, as an effective Tph-1 binder identified by SPR (estimated KD: 6.82  $\mu\text{M}$ ), inhibited the protein and mRNA expression of Tph-1 and reduced the serum and intestinal serotonin content, but had no effect on brain serotonin. In addition, in ovariectomized rats, oral administration of **316** increased serum levels of N-terminal propeptide (a marker of bone formation) of type 1 procollagen (P1NP) and improved bone microstructure without estrogenic side effects [211].

The pyrazine derivatives **317** and **318** of boswellic acid showed obvious antitumor effects. The  $\text{IC}_{50}$  values of compound **317** on A2780, HT-29, and A375 cells were 15.7, 22.7, and 12.8  $\mu\text{M}$ . The  $\text{IC}_{50}$  values of compound **318** were 13.7, 12.2, and 2.1  $\mu\text{M}$  [212].

Wu et al. synthesized 18 $\beta$ -glycyrrtinic acid derivative **319** by introducing piperazine into C-2 after the hydroxyl group in C-3 was oxidized and evaluated its antibacterial activity. Compound **319** pairs of *Staphylococcus aureus* (ATCC 6538), *Staphylococcus aureus* (ATCC 29213), and the strain *Staphylococcus epidermidis* (ATCC 12228) showed obvious inhibition, and the  $\text{MIC}_{50}$  and  $\text{MBC}_{50}$  values were 6.25 and 12.5  $\mu\text{M}$ , respectively [213].

Compound **320** showed a greater inhibitory effect on Gram-positive bacteria than glycyrrhetic acid. Questions about *Staphylococcus aureus subsp. aureus* (ATCC 29213), *Staphylococcus epidermidis* (ATCC 12228), and the MIC value of *Staphylococcus aureus* (ATCC 6538) was 2.72  $\mu\text{g}/\text{mL}$ . The inhibitory activity was similar to that of ampicillin. In vivo, compound **320** was also shown to have anti-inflammatory effects, and 40.0 mg/mL gavage reduced approximately 59.69% of TPA-induced ear edema in mice. Immunohistochemical

results showed that inhibition was related to inhibition of TPA-induced upregulation of the pro-inflammatory cytokines TNF- $\alpha$  and IL-1 $\beta$ . Furthermore, compound **320** significantly reduced the expression level of p65 in the NF- $\kappa$ B signaling pathway [214].




**Figure 32.** Other pentacyclic triterpenes–pyrazine derivatives **315–320**.

Xu et al. synthesized a series of C14 heterocyclic substituted epi-triptolide derivatives. Among them, the pyrazine derivatives **321** (Figure 33) showed certain inhibitory effects on SKOV-3 and PC-3 cell lines, with IC<sub>50</sub> values of 368.7 nM and 157 nM. The activity was higher than epitriptolide (SKOV-3, IC<sub>50</sub> = 790 nM; PC-3, IC<sub>50</sub> = 1320 nM) [215].

Wei et al. obtained derivative **322** by esterification and etherification of 14-dehydroxy-11,12-didehydroandrographolide. Compound **322** showed obvious inhibitory effects on A549, DU145, KB, and KBV in cell lines with IC<sub>50</sub> values of 4.87, 8.63, 8.24, and 9.19  $\mu$ M. The activity of compound **322** exceeded that of andrographolide (A549, IC<sub>50</sub> = 13.37  $\mu$ M; DU145, IC<sub>50</sub> = 15.99  $\mu$ M; KB, IC<sub>50</sub> = 13.18  $\mu$ M; KBV in, IC<sub>50</sub> = 13.82  $\mu$ M) [216].

Grigoropoulou et al. synthesized a series of dehydroabietic acid–chalcone heterozygotes. Compound **323** containing pyrazine showed certain inhibitory effects on MDA-MB-231 and Hs578T cell lines with IC<sub>50</sub> values of 18.01 and 23.11  $\mu$ M. However, compound **323** also showed some toxicity to fibroblasts with an IC<sub>50</sub> value of 20.47  $\mu$ M [217].



**Figure 33.** Other terpenes–pyrazine derivatives 321–328.

Zhao et al. synthesized a series of dehydroabietylamine derivatives containing pyrazine cycloheterocyclic rings. Anti-MCF-7 activity of compounds **324** and **325** increased (IC<sub>50</sub>: 8.81 and 6.66 μM) compared to dehydroabietylamine (IC<sub>50</sub>: 19.45 μM). However, the activity of **324** and **325** against other cells such as HeLa, HepG-2, A549, and HUVEC was lower than that of dehydroabietylamine [218].

Wang et al. designed and synthesized ligustrazine–deoxycholic acid/cholic acid derivatives as antitumor drugs. The IC<sub>50</sub> values of compounds **326** and **327** against the BEL-7402, A549, HCT-8, BGC-823, and A2780 cell lines were 5.472–8.012 μg/mL [79].

Zhao et al. found that 2-Pyrazine-PPD (**328**) showed inhibitory activity in the gastric cancer BGC-823 cell line (IC<sub>50</sub> = 11.52 μM). There is little toxicity to normal cells (human gas-

tric epithelial cell line GES-1). Further studies showed that 2-Pyrazine-PPD (**328**) induced apoptosis of BGC-803 cancer cells through the mitochondrial pathway. Ros production was significantly increased in BGC-803 cancer cells treated with 2-Pyrazine-PPD (**328**). Therefore, 2-Pyrazine-PPD (**328**) exhibits anticancer activity through ROS-mediated apoptosis of gastric cancer cells and stress of the endoplasmic reticulum [219].

Xu et al. introduced piperazine in C-14 to synthesize Rabbesin derivatives for **329** (Figure 34) and evaluated their antibacterial activity. Compound **329** showed significant inhibitory effects on *Mycobacterium phlei* (ATCC 355), *Mycobacterium smegmatis* (ATCC 19420), and *Mycobacterium marinum* (ATCC 927). The MIC<sub>50</sub> values are 4, 32, and 32 μM [220].




Figure 34. Other terpenes–pyrazine derivatives 329–335.

Xu et al. synthesized **330**, an enmein derivative containing pyrazine, and studied its bacteriostatic effect. Compound **330** showed an obvious inhibitory effect on *Mycobacterium phlei* (ATCC 355) with a MIC<sub>50</sub> of 2 µg/mL [221].

Chen et al. synthesized the C-16 carbonyl derivative **331** using isostevia as the raw material and evaluated its anticoagulant activity. In vitro activity of human FXa showed that **331** (K<sub>i</sub> = 3.603 µM) showed relatively better inhibitory activity than isosteviol (K<sub>i</sub> = 13.4 µM) [222].

Compound **332** showed obvious inhibitory activity against HIV replication in H9 lymphocytes with an IC<sub>50</sub> value of 5.6 µg/mL more than linearol activity (IC<sub>50</sub> = 56.5 µg/mL) [223].

Alla D. Zorina et al. tested the antiviral activity of pyrazine triterpenoids against the influenza virus A/Puerto Rico/8/34 (H1N1). The CC<sub>50</sub> and IC<sub>50</sub> values of compound **333** pairs of influenza virus A/Puerto Rico/8/34 (H1N1) were 21.2 and >11 µg mL<sup>-1</sup>. The CC<sub>50</sub> and IC<sub>50</sub> values of compound **334** were 34.2 and 8.2 µg mL<sup>-1</sup>. The IC<sub>50</sub> values of compound **335** were 33 µg mL<sup>-1</sup> [196].

The results of α-glucosidase inhibitory activity in vitro showed that compound **334** exhibited certain inhibitory activity, with IC<sub>50</sub> values of 97.7 µM, respectively, which exceeded the activity of acarbose (IC<sub>50</sub> = 397.6 µM) [224].

### 2.10. Alkaloid–Pyrazine Hybridization

Nishiyama et al. synthesized a 4-pyrazine substituted colchicine derivative **336** (Figure 35). Compound **336** showed moderate cytotoxicity against three human cancer cell lines (A549, HT-29, and HCT116), with IC<sub>50</sub> values of 37.4, 19.4, and 33.0 µM [225].





Figure 35. Alkaloid–pyrazine derivatives 336–344.

In order to improve the antitumor activity of camptothecin, Li et al. designed and synthesized a series of 10 substituted camptothecin derivatives. Compound **337** showed the strongest inhibitory effect on the MCF-7 cell line with an  $IC_{50}$  value of 0.1  $\mu$ M. Compound **338** showed the strongest inhibitory effect on HCT-8 and BEL-7402 cell lines with  $IC_{50}$  values of 0.08 and 0.26  $\mu$ M [226].

Sinomenine derivatives showed stronger TNF- $\alpha$  inhibitory activity than sinomenine. Compounds **339–343** inhibited the production of TNF- $\alpha$  in mice peritoneal macrophages stimulated by LPS in vitro at a concentration of 10  $\mu$ M, and the inhibitory rate was more than 95% [227].

Compound **344** inhibited TNF- $\alpha$ -induced NF- $\kappa$ B activation in a dose-dependent manner and showed a significant in vivo therapeutic effect on mice models of experimental autoimmune uveitis disease [228].

Watanabe et al. reported on a morphinan derivative of the oxazatricyclodecane skeleton and tested its opioid receptor agonist activity. Pyrazine-containing compound **345** (Figure 36) showed a high affinity for all types of receptors (DOR, MOR, and KOR) [229].



**Figure 36.** Alkaloid-pyrazine derivatives **345–348**.

Ananthan et al. synthesized pyridomorphinans with aromatic or heterocyclic substitutions at the 5' position of the morphinan pyridine ring and evaluated the binding and functional activity of opioid receptors  $\delta$ ,  $\mu$ , and  $\kappa$ . Pyrazine-containing compounds **346** and **347** show significant affinity for these three receptors, with  $K_i$  values ranging from 2.3 to 16 nM.

The spinal selective mu-kappa agonist NNTA selectively activates the mu-kappa isomer in HEK-293 cells and produces an unusually potent antipain response after administration in the mouse intrasheath (i.t.) [230]. The quinoline analog **348** of NNTA is a potent agonist ( $ED_{50}$  values of 50.76 and 757.2 pmol, respectively) with a 15-fold increase in spinal cord efficacy in both in vitro and in vitro perfusion pathways. In particular, **348** showed no significant tolerance to either mode of administration [231].

### 3. Conclusions

Natural products derived from microorganisms, plants, and animals are a rich source of effective drugs with significant structural diversity and biological properties, which offer the possibility for researchers to develop new molecules to treat disease [232]. Over

the past few decades, drugs that directly or indirectly replace natural product derivatives and analogs have played an important role in the fight against disease [233]. Natural products have a wide range of biological activities, but their activity is not strong and often has the shortcomings of low bioavailability and poor solubility [234]. Therefore, to improve their physical properties and ADME, it is important to make the necessary structural modifications to them. Through a literature review, it is found that pyrazine stents have considerable biological relevance in anti-osteoporosis, antiviral, anti-diabetic, anti-inflammatory, anti-thrombotic, anti-parasitic, anti-malaria, antibacterial, anticancer, and other studies, leading to the emergence of many strong bioactive pyrazine compounds.

Although much progress has been made in the pharmacology of natural product–pyrazine complexes, the following research opportunities remain to be further investigated: Since many studies have not reported detailed studies of structural modifications of lead compounds, a complete SAR study of natural product–pyrazine complexes is needed. Detailed SAR studies may reveal more active compounds. Furthermore, because pyrazines have a variety of biological activities and multitarget properties, most natural product–pyrazine derivatives do not have specific drug adaptability, hindering the development of these derivatives from laboratory to clinical applications; therefore, the *in vivo* activity of the natural product–pyrazine hybrid needs to be evaluated. Additionally, most natural products–pyrazine derivatives have no clear targets. To solve this problem, using reasonable drug design strategies such as computer-aided drug design, the target identification of a powerful natural product–pyrazine hybrid was studied, and the compounds were optimized. Finally, pharmacophore combinations and structure-based drug design strategies should be widely used in the following studies to develop more novel, more active, and more specific natural products–pyrazine derivatives, and the mechanism of action of these compounds should be studied in detail.

In conclusion, this review provides a favorable reference for the study of compounds containing pyrazine fragments. Pyrazine derivatives of natural products still have a wide range of research prospects and are worth further research and development. With the rapid development of combinatorial chemistry, rational drug design, and chemical proteomics, we believe that researchers will find more novel derivatives of pyrazines with good biological activity and wide application.

**Author Contributions:** Conceptualization and review methodologies—G.-Q.C., H.-Y.G. and T.L.; Original draft writing—G.-Q.C. and T.L.; Editing—All authors; Figure creation—All authors; Revision—T.L. and X.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was financially supported by the Educational Department of Liaoning Province (No. LJKMZ20221801), the Doctoral Research Foundation of Shenyang Medical College (No. 20205041), the Higher Education Discipline Innovation Project (D18012), the National Natural Science Foundation of China (Nos. 81960626, 82060628, 82204310), the Key Projects of Jilin Province Science and Technology Development Plan (No. 20200404130YY), the Jilin Scientific and Technological Development Program (Nos. YDZJ202301ZYTS440, YDZJ202301ZYTS143), and the Education Department Project of Jilin (JJKH20220559KJ, JJKH20220563KJ).

**Conflicts of Interest:** The authors declare no conflict of interest.

## List of Abbreviations

HCV	Hepatitis C virus
RdRp	RNA-dependent RNA polymerase
SRB	Sulforhodamine B
HMEC-2	Human microvascular endothelial cell line
SH-SY5Y	Human neuroblastoma cell line
ChEs	Cholinesterase
ROS	reactive oxygen species
Cyt-c	Cytochrome-C
ADP	Adenosine diphosphate

PARP	Poly(ADP-ribose) polymerase
MCAO	Middle cerebral artery occlusion
HBV	Hepatitis B virus
Tph-1	Tryptophan hydroxylase 1
ADME	Absorption, distribution, metabolism, excretion
LPS	Lipopolysaccharide
NO	Nitric oxide
NAs	Nanoaggregates
DTT	Dithiothreitol
PPT	Podophyllotoxin

## References

- Saleh, S.S.; AL-Salihi, S.S.; Mohammed, I.A. Biological activity Study for some heterocyclic compounds and their impact on the gram positive and negative bacteria. *Energy Procedia* **2019**, *157*, 296–306. [[CrossRef](#)]
- Barreca, M.; Spanò, V.; Rocca, R.; Bivacqua, R.; Gualtieri, G.; Raimondi, M.V.; Gaudio, E.; Bortolozzi, R.; Manfreda, L.; Bai, R.; et al. Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas. *Eur. J. Med. Chem.* **2023**, *254*, 115372. [[CrossRef](#)] [[PubMed](#)]
- Bivacqua, R.; Barreca, M.; Spanò, V.; Raimondi, M.V.; Romeo, I.; Alcaro, S.; Andrei, G.; Barraja, P.; Montalbano, A. Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors. *Eur. J. Med. Chem.* **2023**, *249*, 115136. [[CrossRef](#)] [[PubMed](#)]
- Huigens, R.W., III; Brummel, B.R.; Tenneti, S.; Garrison, A.T.; Xiao, T. Pyrazine and Phenazine Heterocycles: Platforms for Total Synthesis and Drug Discovery. *Molecules* **2022**, *27*, 1112. [[CrossRef](#)]
- Miniyar, P.B.; Murumkar, P.R.; Patil, P.S.; Barmade, M.A.; Bothara, K.G. Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review. *Mini-Rev. Med. Chem.* **2013**, *13*, 1607–1625. [[CrossRef](#)]
- Choudhary, D.; Garg, S.; Kaur, M.; Sohal, H.S.; Malhi, D.S.; Kaur, L.; Verma, M.; Sharma, A.; Mutreja, V. Advances in the Synthesis and Bio-Applications of Pyrazine Derivatives: A Review. *Polycycl. Aromat. Compd.* **2023**, *43*, 4512–4578. [[CrossRef](#)]
- Masaret, G.S.; Farghaly, T.A.; Al-Hussain, S.A.; Zaki, M.E.A.; Alsaedi, A.M.R.; Muhammad, Z.A. Site-Selectivity of the Reaction of 3-Amino-4-Cyano-5-Phenyl-1H-Pyrrole-2-Carboxylic Acid Amide with  $\alpha$ -Halocarbonyl Compounds. Antimicrobial Activity and Docking Study for COVID-19 of the Products. *Polycycl. Aromat. Compd.* **2023**, *43*, 7110–7126. [[CrossRef](#)]
- Christie, A.W.; McCormick, D.K.T.; Emmison, N.; Kraemer, F.B.; Alberti, K.G.M.M.; Yeaman, S.J. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. *Diabetologia* **1996**, *39*, 45–53. [[CrossRef](#)]
- Loffing, J.; Kaissling, B. Sodium and calcium transport pathways along the mammalian distal nephron: From rabbit to human. *Am. J. Physiol.* **2003**, *284*, F628. [[CrossRef](#)]
- Chalfant, M.L.; Peterson-Yantorno, K.; O'Brien, T.G.; Civan, M.M. Regulation of epithelial Na<sup>+</sup> channels from M-1 cortical collecting duct cells. *Am. J. Physiol.* **1996**, *271*, F861. [[CrossRef](#)]
- Adams, J.; Kauffman, M. Development of the Proteasome Inhibitor Velcade (Bortezomib). *Cancer Investig.* **2004**, *22*, 304–311. [[CrossRef](#)] [[PubMed](#)]
- Curran, M.P.; McKeage, K. Bortezomib: A review of its use in patients with multiple myeloma. *Drugs* **2009**, *69*, 859–888. [[CrossRef](#)]
- Kouroukis, T.C.; Baldassarre, F.G.; Haynes, A.E.; Imrie, K.; Reece, D.E.; Cheung, M.C. Bortezomib in multiple myeloma: Systematic review and clinical considerations. *Curr. Oncol.* **2014**, *21*, e573–e603. [[CrossRef](#)]
- Prendergast, B.D. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. *Clin. Pharm.* **1984**, *3*, 473–485. [[PubMed](#)]
- Bonanni, G.; Ciccariello, M.; Mancini, P.; Pace, V.; Sagliaschi, G. Concomitant ceco-appendicular and urinary tuberculosis. Description of two rare cases: Physiopathological and diagnostic remarks. *Riv. Eur. Sci. Med. Farmacol.* **1993**, *15*, 171–174. [[PubMed](#)]
- Zimhony, O.; Cox, J.S.; Welch, J.T.; Vilcheze, C.; Jacobs, W.R., Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. *Nat. Med.* **2000**, *6*, 1043–1047. [[CrossRef](#)]
- Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis. *Cancer Res.* **2004**, *64*, 6424–6431. [[CrossRef](#)]
- Barth, F. CB1 cannabinoid receptor antagonist. *Annu. Rep. Med. Chem.* **2005**, *40*, 103–118.
- Foreman, M.M.; Hanania, T.; Stratton, S.C.; Wilcox, K.S.; White, H.S.; Stables, J.P.; Eller, M. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. *Pharmacol. Biochem. Behav.* **2008**, *89*, 523–534. [[CrossRef](#)] [[PubMed](#)]
- Mills, E.J.; Wu, P.; Spurden, D.; Ebbert, J.O.; Wilson, K. Efficacy of pharmacotherapies for short-term smoking abstinence: A systematic review and meta-analysis. *Harm. Reduct. J.* **2009**, *6*, 25. [[CrossRef](#)]
- James, N.D.; Growcott, J.W. ZD4054. *Drugs Future* **2009**, *34*, 624–633. [[CrossRef](#)]
- De la Rosa, D.A.; Canessa, C.M.; Fyfe, G.K.; Zhang, P. Structure and regulation of amiloride-sensitive sodium channels. *Annu. Rev. Physiol.* **2000**, *62*, 573–594. [[CrossRef](#)] [[PubMed](#)]
- Shen, J.; Serby, M.; Reed, A.; Lee, A.J.; Zhang, X.; Marsh, K.; Khatri, A.; Menon, R.; Kavetskaia, O.; Fischer, V. Metabolism and disposition of the hepatitis C protease inhibitor paritaprevir in humans. *Drug Metab. Dispos.* **2016**, *44*, 1164–1173. [[CrossRef](#)]

24. Monti, J.M.; Pandi-Perumal, S.R. Eszopiclone: Its use in the treatment of insomnia. *Neuropsychiatr. Dis. Treat.* **2007**, *3*, 441–453. [[PubMed](#)]
25. McCrae, C.S.; Ross, A.; Stripling, A.; Dautovich, N.D. Eszopiclone for late-life insomnia. *Clin. Investig. Aging* **2007**, *2*, 313–326.
26. Balogh, A. Drug for the treatment of sleep disorders—Review. *Z. Arztl. Fortbild. Qualitatssich.* **2001**, *95*, 11–16.
27. Lee, S.; LaCour, T.G.; Fuchs, P.L. Chemistry of trisdecacyclic pyrazine antineoplastics: The cephalostatins and ritterazines. *Chem. Rev.* **2009**, *109*, 2275–2314. [[CrossRef](#)] [[PubMed](#)]
28. Fukuzawa, S.; Matsunaga, S.; Fusetani, N. Isolation and structure elucidation of ritterazines B and C, highly cytotoxic dimeric steroidal alkaloids, from the tunicate *Ritterella tokioka*. *J. Org. Chem.* **1995**, *60*, 608. [[CrossRef](#)]
29. Guo, Q.; Xu, M.; Guo, S.; Zhu, F.; Xie, Y.; Shen, J. The complete synthesis of favipiravir from 2-aminopyrazine. *Chem. Pap.* **2019**, *73*, 1043–1051. [[CrossRef](#)]
30. Agrawal, U.; Raju, R.; Udawadia, Z.F. Favipiravir: A new and emerging antiviral option in COVID-19. *Med. J. Armed Forces India* **2020**, *76*, 370–376. [[CrossRef](#)]
31. Manabe, T.; Kambayashi, D.; Akatsu, H.; Kudo, K. Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis. *BMC Infect. Dis.* **2021**, *21*, 489. [[CrossRef](#)] [[PubMed](#)]
32. Chill, L.; Aknin, M.; Kashman, Y. Barrenazine A and B; two new cytotoxic alkaloids from an unidentified tunicate. *Org. Lett.* **2003**, *5*, 2433–2435. [[CrossRef](#)] [[PubMed](#)]
33. Zhu, L.H.; Chen, C.; Wang, H.; Ye, W.C.; Zhou, G.X. Indole alkaloids from *Alocasia macrorrhiza*. *Chem. Pharm. Bull.* **2012**, *60*, 670–673. [[CrossRef](#)] [[PubMed](#)]
34. Eriksson, A.; Hermanson, M.; Wickström, M.; Lindhagen, E.; Ekholm, C.; Jenmalm Jensen, A.; Löthgren, A.; Lehmann, F.; Larsson, R.; Parrow, V.; et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. *Blood Cancer J.* **2012**, *2*, e81. [[CrossRef](#)]
35. Bremberg, U.; Eriksson-Bajtner, J.; Lehmann, F.; Oltner, V.; Soelver, E.; Wennerberg, J. Development of a Synthesis of Kinase Inhibitor AKN028. *Org. Process Res. Dev.* **2018**, *22*, 1360–1364. [[CrossRef](#)]
36. Duran, R.; Zubia, E.; Ortega, M.J.; Naranjo, S.; Salva, J. Novel alkaloids from the red ascidian *Botryllus leachi*. *Tetrahedron* **1999**, *55*, 13225–13232. [[CrossRef](#)]
37. Saito, R.; Tokita, M.; Uda, K.; Ishikawa, C.; Satoh, M. Synthesis and in vitro evaluation of botryllazine B analogues as a new class of inhibitor against human aldose reductase. *Tetrahedron* **2009**, *65*, 3019–3026. [[CrossRef](#)]
38. Liu, Y.; Zhou, Y.; Qiao, J.; Yu, W.; Pan, X.; Zhang, T.; Liu, Y.; Lu, S.E. Phenazine-1-carboxylic Acid Produced by *Pseudomonas chlororaphis* YL-1 Is Effective against *Acidovorax citrulli*. *Microorganisms* **2021**, *9*, 2012. [[CrossRef](#)]
39. Conda-Sheridan, M.; Marler, L.; Park, E.J.; Kondratyuk, T.P.; Jermihov, K.; Mesecar, A.D.; Pezzuto, J.M.; Solkar, R.N.; Fenical, W.; Cushman, M. Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from *Streptomyces* species, strain CNS284. *J. Med. Chem.* **2010**, *53*, 8688–8699. [[CrossRef](#)]
40. Fotso, S.; Santosa, D.A.; Saraswati, R.; Yang, J.; Mahmud, T.; Zabriskie, T.M.; Proteau, P.J. Modified phenazines from an Indonesian *Streptomyces* sp. *J. Nat. Prod.* **2010**, *73*, 472–475. [[CrossRef](#)]
41. Abouelhassan, Y.; Zhang, Y.; Jin, S.; Huigens, R.W., III. Transcript Profiling of MRSA Biofilms Treated with a Halogenated Phenazine Eradicating Agent: A Platform for Defining Cellular Targets and Pathways Critical to Biofilm Survival. *Angew. Chem. Int. Ed. Engl.* **2018**, *57*, 15523–15528. [[CrossRef](#)]
42. Sletta, H.; Degnes, K.F.; Herfindal, L.; Klinkenberg, G.; Fjaervik, E.; Zahlsen, K.; Brunsvik, A.; Nygaard, G.; Aachmann, F.L.; Ellingsen, T.E.; et al. Anti-microbial and cytotoxic 1,6-dihydroxyphenazine-5,10-dioxide (iodinin) produced by *Streptosporangium* sp. DSM 45942 isolated from the fjord sediment. *Appl. Microbiol. Biotechnol.* **2014**, *98*, 603–610. [[CrossRef](#)] [[PubMed](#)]
43. Jiang, J.; Guiza Beltran, D.; Schacht, A.; Wright, S.; Zhang, L.; Du, L. Functional and Structural Analysis of Phenazine O-Methyltransferase LaPhzM from *Lysobacter antibioticus* OH13 and One-Pot Enzymatic Synthesis of the Antibiotic Myxin. *ACS Chem. Biol.* **2018**, *13*, 1003–1012. [[CrossRef](#)] [[PubMed](#)]
44. Avtsyn, A.P.; Pershin, G.N.; Trager, R.S.; Shakhlamov, V.A.; Padejskaia, E.N. Activity of di-N-hydroxyquinoxaline and depot-sulfanilamide derivatives in experimental NAG infection. *Biull. Eksp. Biol. Med.* **1982**, *93*, 76–78. [[CrossRef](#)]
45. Samata, K.; Yamagishi, T.; Ichihara, T.; Nanaumi, K.; Ikeda, T.; Ikeya, H.; Kuraishi, A.; Nakaike, S.; Kashiwagi, K.; Igarashi, K. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190. *Cancer Chemother. Pharmacol.* **2002**, *50*, 367–372. [[CrossRef](#)]
46. Tarui, M.; Doi, M.; Ishida, T.; Inoue, M.; Nakaike, S.; Kitamura, K. DNA-binding characterization of a novel antitumor benzo[a]phenazine derivative NC-182: Spectroscopic and viscometric studies. *Biochem. J.* **1994**, *304*, 271. [[CrossRef](#)]
47. Montazeri, K.; Bellmunt, J. Erdafitinib for the treatment of metastatic bladder cancer. *Expert Rev. Clin. Pharmacol.* **2020**, *13*, 1–6. [[CrossRef](#)] [[PubMed](#)]
48. Weng, W.; Hong, J.; Owusu-Ansah, K.G.; Chen, B.; Zheng, S.; Jiang, D. Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: Role of mTOR/4E-BP1 signal pathway. *Heliyon* **2022**, *8*, e12064. [[CrossRef](#)]
49. Widemann, B.C.; Adamson, P.C. Understanding and managing methotrexate nephrotoxicity. *Oncologist* **2006**, *11*, 694–703. [[CrossRef](#)]
50. Bogani, G.; Monk, B.J.; Coleman, R.L.; Vergote, I.; Oakin, A.; Ray-Coquard, I.; Mariani, A.; Scambia, G.; Raspagliesi, F.; Bolognese, B. Selinexor in patients with advanced and recurrent endometrial cancer. *Curr. Probl. Cancer* **2023**, 100963. [[CrossRef](#)]

51. Mizuta, H.; Okada, K.; Araki, M.; Adachi, J.; Takemoto, A.; Kutkowska, J.; Maruyama, K.; Yanagitani, N.; Oh-Hara, T.; Watanabe, K.; et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. *Nat. Commun.* **2021**, *12*, 1261. [[CrossRef](#)] [[PubMed](#)]
52. Wang, S.J.; Huang, C.F.; Yu, M.L. Elbasvir and grazoprevir for the treatment of hepatitis C. *Expert Rev. Anti-Infect. Ther.* **2021**, *19*, 1071–1081. [[CrossRef](#)]
53. Muir, A.J. Telaprevir for the treatment of chronic hepatitis C infection. *Expert Rev. Anti-Infect. Ther.* **2011**, *9*, 1105–1114. [[CrossRef](#)] [[PubMed](#)]
54. Horisberger, J.D.; Giebisch, G. Potassium-sparing diuretics. *Kidney Blood Press. Res.* **1987**, *10*, 198–220. [[CrossRef](#)] [[PubMed](#)]
55. van Gool, J.D.; Hirche, H.; Lax, H.; De Schaepdrijver, L. Folic acid and primary prevention of neural tube defects: A review. *Reprod. Toxicol.* **2018**, *80*, 73–84. [[CrossRef](#)]
56. Sitbon, O.; Channick, R.; Chin, K.M.; Frey, A.; Gaine, S.; Galiè, N.; Ghofrani, H.A.; Hoepfer, M.M.; Lang, I.M.; Preiss, R.; et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. *N. Engl. J. Med.* **2015**, *373*, 2522–2533. [[CrossRef](#)]
57. Hussain, Z.; Zhu, J.; Ma, X. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. *Drug Metab. Dispos.* **2021**, *49*, 679–682. [[CrossRef](#)]
58. Fiori, G.; Saglini, V.; Bertini, F.; Domenighetti, G.; Mombelli, G. Severe poisoning with the organophosphorus insecticide thionazine--2 cases with the development of adult respiratory distress syndrome (ARDS). *Schweiz. Med. Wochenschr.* **1987**, *117*, 399–401.
59. Chen, W.; Chen, W.; Zhu, J.; Chen, N.; Lu, Y. Potent Anti-Inflammatory Activity of Tetramethylpyrazine Is Mediated through Suppression of NF- $\kappa$ . *Iran. J. Pharm. Res. IJPR* **2016**, *15*, 197–204.
60. Lidin-Janson, G. Sulphonamides in the treatment of acute Escherichia coli infection of the urinary tract in women. Clinical and ecological effects of sulphasomidine and sulphalene. *Scand. J. Infect. Dis.* **1977**, *9*, 211–217. [[CrossRef](#)]
61. Oh, D.J.; Chen, J.L.; Vajaranant, T.S.; Dikopf, M.S. Brimonidine tartrate for the treatment of glaucoma. *Expert Opin. Pharmacother.* **2019**, *20*, 115–122. [[CrossRef](#)] [[PubMed](#)]
62. Foster, B.J.; Claggett-Carr, K.; Shoemaker, D.D.; Suffness, M.; Plowman, J.; Trissel, L.A.; Grieshaber, C.K.; Leyland-Jones, B. Echinomycin: The first bifunctional intercalating agent in clinical trials. *Investig. New Drugs* **1985**, *3*, 403–410. [[CrossRef](#)] [[PubMed](#)]
63. Fisherman, J.S.; Osborn, B.L.; Chun, H.G.; Plowman, J.; Smith, A.C.; Christian, M.C.; Zaharko, D.S.; Shoemaker, R.H. Chloroquinoline sulfonamide: A sulfanilamide antitumor agent entering clinical trials. *Investig. New Drugs* **1993**, *11*, 1–9. [[CrossRef](#)] [[PubMed](#)]
64. Clanner-Engelshofen, B.M.; Bernhard, D.; Dargatz, S.; Flaig, M.J.; Gieler, U.; Kinberger, M.; Klövekorn, W.; Kuna, A.C.; Läuchli, S.; Lehmann, P.; et al. S2k guideline: Rosacea. *J. Dtsch. Dermatol. Ges.* **2022**, *20*, 1147–1165. [[CrossRef](#)]
65. Moore, D.J.; Brodfuehrer, J.I.; Wilke, T.J.; Powis, G. Disposition and metabolism of the antitumor agent pyrazine-2-diazo hydroxide in mouse and beagle dog. *Cancer Chemother. Pharmacol.* **1988**, *21*, 269. [[CrossRef](#)]
66. Mori, M.; Supuran, C.T. Acipimox inhibits human carbonic anhydrases. *J. Enzym. Inhib. Med. Chem.* **2022**, *37*, 672–679. [[CrossRef](#)]
67. Williams, R.L.; Trenholme, G.M.; Carson, P.E.; Frischer, H.; Rieckmann, K.H. The influence of acetylator phenotype on the response to sulfolene in individuals with chloroquine-resistant falciparum malaria. *Am. J. Trop. Med. Hyg.* **1978**, *27*, 226–231. [[CrossRef](#)] [[PubMed](#)]
68. France, C.P.; Winger, G.; Medzihradsky, F.; Seggel, M.R.; Rice, K.C.; Woods, J.H. Mirfentanil: Pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. *J. Pharmacol. Exp. Ther.* **1991**, *258*, 502–510.
69. Beaulieu, P.L.; Gillard, J.; Jolicoeur, E.; Duan, J.; Garneau, M.; Kukulj, G.; Poupart, M.A. From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3658–3663. [[CrossRef](#)] [[PubMed](#)]
70. Rong, F.; Chow, S.; Yan, S.; Larson, G.; Hong, Z.; Wu, J. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1663–1666. [[CrossRef](#)]
71. Ma, S.; Deng, J.; Li, B.; Li, X.; Yan, Z.; Zhu, J.; Chen, G.; Wang, Z.; Jiang, H.; Miao, L.; et al. Development of Second-Generation Small-Molecule RhoA Inhibitors with Enhanced Water Solubility, Tissue Potency, and Significant in vivo Efficacy. *ChemMedChem* **2015**, *10*, 193–206. [[CrossRef](#)] [[PubMed](#)]
72. Deng, J.; Feng, E.; Ma, S.; Zhang, Y.; Liu, X.; Li, H.; Huang, H.; Zhu, J.; Zhu, W.; Shen, X.; et al. Design and synthesis of small molecule RhoA inhibitors: A new promising therapy for cardiovascular diseases? *J. Med. Chem.* **2011**, *54*, 4508–4522. [[CrossRef](#)] [[PubMed](#)]
73. Qian, K.; Wang, L.; Cywin, C.L.; Farmer, B.T.; Hickey, E.; Homon, C.; Jakes, S.; Kashem, M.A.; Lee, G.; Leonard, S.; et al. Hit to Lead Account of the Discovery of a New Class of Inhibitors of Pim Kinases and Crystallographic Studies Revealing an Unusual Kinase Binding Mode. *J. Med. Chem.* **2009**, *52*, 1814–1827. [[CrossRef](#)] [[PubMed](#)]
74. Zhang, W.X.; Wang, H.; Cui, H.R.; Guo, W.B.; Zhou, F.; Cai, D.S.; Xu, B.; Jia, X.H.; Huang, X.M.; Yang, Y.Q.; et al. Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect. *Eur. J. Med. Chem.* **2019**, *183*, 111695. [[CrossRef](#)] [[PubMed](#)]
75. Li, G.; Hong, G.; Li, X.; Zhang, Y.; Xu, Z.; Mao, L.; Feng, X.; Liu, T. Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids. *Eur. J. Med. Chem.* **2018**, *148*, 238–254. [[CrossRef](#)]
76. Wang, P.; Zhao, R.; Yan, W.; Zhang, X.; Zhang, H.; Xu, B.; Chu, F.; Han, Y.; Li, G.; Liu, W.; et al. Neuroprotection by new ligustrazine-cinnamonic acid derivatives on CoCl<sub>2</sub>-induced apoptosis in differentiated PC12 cells. *Bioorg. Chem.* **2018**, *77*, 360–369. [[CrossRef](#)]

77. Chen, H.; Li, G.; Zhan, P.; Liu, X. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. *Eur. J. Med. Chem.* **2011**, *46*, 5609–5615. [[CrossRef](#)]
78. Chen, H.; Li, G.; Zhan, P.; Li, H.; Wang, S.; Liu, X. Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents. *MedChemComm* **2014**, *5*, 711–718. [[CrossRef](#)]
79. Wang, P.; She, G.; Yang, Y.; Li, Q.; Zhang, H.; Liu, J.; Cao, Y.; Xu, X.; Lei, H. Synthesis and biological evaluation of new ligustrazine derivatives as anti-tumor agents. *Molecules* **2012**, *17*, 4972–4985. [[CrossRef](#)]
80. Li, G.; Xu, X.; Xu, K.; Chu, F.; Song, J.; Zhou, S.; Xu, B.; Gong, Y.; Zhang, H.; Zhang, Y.; et al. Ligustrazinyl amides: A novel class of ligustrazine-phenolic acid derivatives with neuroprotective effects. *Chem. Cent. J.* **2015**, *9*, 9. [[CrossRef](#)]
81. Balasubramaniam, S.; Vijayan, S.; Goldman, L.V.; May, X.A.; Dodson, K.; Adhikari, S.; Rivas, F.; Watkins, D.L.; Stoddard, S.V. Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition. *Beilstein J. Org. Chem.* **2020**, *16*, 628–637. [[CrossRef](#)]
82. Hu, Y.S.; Han, X.; Yu, P.J.; Jiao, M.M.; Liu, X.H.; Shi, J.B. Novel paeonol derivatives: Design, synthesis and anti-inflammatory activity in vitro and in vivo. *Bioorg. Chem.* **2020**, *98*, 103735. [[CrossRef](#)]
83. Zou, Y.; Yan, C.; Zhang, H.; Xu, J.; Zhang, D.; Huang, Z.; Zhang, Y. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents. *Eur. J. Med. Chem.* **2017**, *138*, 313–319. [[CrossRef](#)]
84. Qian, J.; Xu, Z.; Zhu, P.; Meng, C.; Liu, Y.; Shan, W.; He, A.; Gu, Y.; Ran, F.; Zhang, Y.; et al. A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma. *J. Nat. Prod.* **2021**, *84*, 3161–3168. [[CrossRef](#)]
85. Zou, Y.; Zhao, D.; Yan, C.; Ji, Y.; Liu, J.; Xu, J.; Lai, Y.; Tian, J.; Zhang, Y.; Huang, Z. Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells In Vitro and In Vivo. *J. Med. Chem.* **2018**, *61*, 1821–1832. [[CrossRef](#)]
86. Ma, X.Y.; Wang, D.P.; Wei, G.; Zhou, Q.D.; Gan, X.H. Synthesis and anticancer activity of chalcone-quinoxalin conjugates. *Synth. Commun.* **2021**, *51*, 1363–1372. [[CrossRef](#)]
87. Wang, H.; Zhang, W.; Cheng, Y.; Zhang, X.; Xue, N.; Wu, G.; Chen, M.; Fang, K.; Guo, W.; Zhou, F.; et al. Design, Synthesis and Biological Evaluation of Ligustrazine-Flavonoid Derivatives as Potential Anti-Tumor Agents. *Molecules* **2018**, *23*, 2187. [[CrossRef](#)] [[PubMed](#)]
88. Srilaxmi, D.; Sreenivasulu, R.; Mak, K.K.; Pichika, M.R.; Jadav, S.S.; Ahsan, M.J.; Rao, M.V.B. Design, synthesis, anticancer evaluation and molecular docking studies of chalcone linked pyrido[4,3-b]pyrazin-5(6H)-one derivatives. *J. Mol. Struct.* **2021**, *1229*, 129851. [[CrossRef](#)]
89. Xia, R.J.; Guo, T.; He, J.; Chen, M.; Su, S.J.; Jiang, S.C.; Tang, X.; Chen, Y.; Xue, W. Antimicrobial evaluation and action mechanism of chalcone derivatives containing quinoxaline moiety. *Monatsh. Chem.* **2019**, *150*, 1325–1334. [[CrossRef](#)]
90. Besharati-Seidani, T.; Keivanloo, A.; Kaboudin, B.; Yoshida, A.; Yokomatsu, T. Regioselective synthesis of 2,3-disubstituted 1-alkyl pyrrolo[2,3-b] quinoxalines through palladium-catalyzed Heck reaction of chalcones and evaluation of their anti-bacterial activities. *Tetrahedron* **2018**, *74*, 2350–2358. [[CrossRef](#)]
91. Luo, Y.; Wu, W.; Zha, D.; Zhou, W.; Wang, C.; Huang, J.; Chen, S.; Yu, L.; Li, Y.; Huang, Q.; et al. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. *Bioorg. Med. Chem. Lett.* **2021**, *47*, 128230. [[CrossRef](#)] [[PubMed](#)]
92. Wang, M.; Cao, G.; Zhou, J.; Cai, J.; Ma, X.; Liu, Z.; Huang, X.; Wang, H. Ligustrazine-Derived Chalcones-Modified Platinum(IV) Complexes Intervene in Cisplatin Resistance in Pancreatic Cancer through Ferroptosis and Apoptosis. *J. Med. Chem.* **2023**, *66*, 13587–13606. [[CrossRef](#)]
93. Nkepan, G.; Bio, M.; Rajaputra, P.; Awuah, S.G.; You, Y. Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor. *Bioconjug. Chem.* **2014**, *25*, 2175–2188. [[CrossRef](#)]
94. Böhm, M.; Rosenkranz, S.; Laufs, U. Alcohol and red wine: Impact on cardiovascular risk. *Nephrol. Dial. Transplant.* **2004**, *19*, 11–16. [[CrossRef](#)] [[PubMed](#)]
95. Deng, L.; Guo, X.; Zhai, L.; Song, Y.; Chen, H.; Zhan, P.; Wu, J.; Liu, X. Ligustrazine derivatives. Part 4: Design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. *Chem. Biol. Drug Des.* **2012**, *79*, 731–739. [[CrossRef](#)] [[PubMed](#)]
96. Chen, L.Z.; Shu, H.Y.; Wu, J.; Yu, Y.L.; Ma, D.; Huang, X.; Liu, M.M.; Liu, X.H.; Shi, J.B. Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. *Eur. J. Med. Chem.* **2021**, *213*, 113174. [[CrossRef](#)]
97. Liang, X.; Sun, Y.; Zeng, W.; Liu, L.; Ma, X.; Zhao, Y.; Fan, J. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate. *Bioorg. Med. Chem.* **2013**, *21*, 178–185. [[CrossRef](#)]
98. Shanmugam, M.K.; Rane, G.; Kanchi, M.M.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Tan, B.K.; Kumar, A.P.; Sethi, G. The multifaceted role of curcumin in cancer prevention and treatment. *Molecules* **2015**, *20*, 2728–2769. [[CrossRef](#)]
99. Iwai, M.; Minematsu, T.; Li, Q.; Iwatsubo, T.; Usui, T. Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein. *Drug Metab. Dispos.* **2011**, *39*, 2314–2320. [[CrossRef](#)]

100. Ai, Y.; Zhu, B.; Ren, C.; Kang, F.; Li, J.; Huang, Z.; Lai, Y.; Peng, S.; Ding, K.; Tian, J.; et al. Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer. *J. Med. Chem.* **2016**, *59*, 1747–1760. [[CrossRef](#)]
101. Singh, R.K.; Rai, D.; Yadav, D.; Bhargava, A.; Balzarini, J.; De Clercq, E. Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid. *Eur. J. Med. Chem.* **2010**, *45*, 1078–1086. [[CrossRef](#)] [[PubMed](#)]
102. Banerjee, S.; Prasad, P.; Hussain, A.; Khan, I.; Kondaiah, P.; Chakravarty, A.R. Remarkable photocytotoxicity of curcumin in HeLa cells in visible light and arresting its degradation on oxovanadium(IV) complex formation. *Chem. Commun.* **2012**, *48*, 7702–7704. [[CrossRef](#)]
103. Banerjee, S.; Pant, I.; Khan, I.; Prasad, P.; Hussain, A.; Kondaiah, P.; Chakravarty, A.R. Remarkable enhancement in photocytotoxicity and hydrolytic stability of curcumin on binding to an oxovanadium(IV) moiety. *Dalton Trans.* **2015**, *44*, 4108–4122. [[CrossRef](#)] [[PubMed](#)]
104. Banaspati, A.; Raza, K.M.; Goswami, T.K. Ni(II) curcumin complexes for cellular imaging and photo-triggered in vitro anticancer activity. *Eur. J. Med. Chem.* **2020**, *204*, 112632. [[CrossRef](#)]
105. Vanco, J.; Travnicek, Z.; Hosek, J.; Malina, T.; Dvorak, Z. Copper(II) Complexes Containing Natural Flavonoid Pomiferin Show Considerable In Vitro Cytotoxicity and Anti-inflammatory Effects. *Int. J. Mol. Sci.* **2021**, *22*, 7626. [[CrossRef](#)] [[PubMed](#)]
106. Velagapudi, U.K.; Langelier, M.F.; Delgado-Martin, C.; Diolaiti, M.E.; Bakker, S.; Ashworth, A.; Patel, B.A.; Shao, X.; Pascal, J.M.; Talele, T.T. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. *J. Med. Chem.* **2019**, *62*, 5330–5357. [[CrossRef](#)] [[PubMed](#)]
107. Dong, Y.; Zhang, X.; Liu, M.; Yang, Y.; Guo, T.; Mao, Y.; Zhang, J.; Fu, X.; Zhao, Y.; Chen, J.; et al. Hybrid molecules of scutellarein and tetramethylpyrazine's active metabolites for ischemic stroke. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 126608. [[CrossRef](#)] [[PubMed](#)]
108. Ghorab, M.M.; Alsaied, M.S.; Al-Ansary, G.H.; Abdel-Latif, G.A.; Abou El Ella, D.A. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers. *Eur. J. Med. Chem.* **2016**, *124*, 946–958. [[CrossRef](#)]
109. Aoki, T.; Hyohdoh, I.; Furuichi, N.; Ozawa, S.; Watanabe, F.; Matsushita, M.; Sakaitani, M.; Morikami, K.; Takanashi, K.; Harada, N.; et al. Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning. *ACS Med. Chem. Lett.* **2014**, *5*, 309–314. [[CrossRef](#)]
110. Kamble, A.A.; Kamble, R.R.; Kumbar, M.N.; Tegginamath, G. Pyridine-catalyzed synthesis of quinoxalines as anticancer and anti-tubercular agents. *Med. Chem. Res.* **2016**, *25*, 1163–1174. [[CrossRef](#)]
111. Sarkar, T.; Kumar, A.; Sahoo, S.; Hussain, A. Mixed-Ligand Cobalt(III) Complexes of a Naturally Occurring Coumarin and Phenanthroline Bases as Mitochondria-Targeted Dual-Purpose Photochemotherapeutics. *Inorg. Chem.* **2021**, *60*, 6649–6662. [[CrossRef](#)]
112. Goel, R.; Luxami, V.; Paul, K. Synthesis, in vitro anticancer activity and SAR studies of arylated imidazo[1,2-a]pyrazine-coumarin hybrids. *RSC Adv.* **2015**, *5*, 37887–37895. [[CrossRef](#)]
113. Halawa, A.H.; Eliwa, E.M.; Hassan, A.A.; Nassar, H.S.; El-Eisawy, R.A.; Ismail, M.; Frese, M.; Shaaban, M.; El-Agrody, A.M.; Bedair, A.H.; et al. Synthesis, in vitro cytotoxicity activity against the human cervix carcinoma cell line and in silico computational predictions of new 4-arylamino-3-nitrocoumarin analogues. *J. Mol. Struct.* **2020**, *1200*, 127047. [[CrossRef](#)]
114. El-Ansary, A.L.; Moustafa, H.; Abdel-Kader, N.S.; Farghaly, A.M. Effect of the formation of silver nano-binuclear complex on the refinement of cytotoxic and antibacterial potency of coumarin Schiff base: Spectroscopy, thermal, X-ray diffraction analyses and density functional theory calculations. *Appl. Organomet. Chem.* **2019**, *33*, e4968. [[CrossRef](#)]
115. Sharma, R.K.; Singh, V.; Tiwari, N.; Butcher, R.J.; Katiyar, D. Synthesis, antimicrobial and chitinase inhibitory activities of 3-amidocoumarins. *Bioorg. Chem.* **2020**, *98*, 103700. [[CrossRef](#)] [[PubMed](#)]
116. Chai, X.; Yu, S.; Wang, X.; Wang, N.; Zhu, Z.; Zhang, D.; Wu, Q.; Cao, Y.; Sun, Q. Synthesis and antifungal activity of novel 7-O-substituted pyridyl-4-methylcoumarin derivatives. *Med. Chem. Res.* **2013**, *22*, 4654–4662. [[CrossRef](#)]
117. Moosavi-Zare, A.R.; Zolfigol, M.A.; Noroozadeh, E.; Zarei, M.; Karamian, R.; Asadbegy, M. Synthesis and characterization of acetic acid functionalized poly(4-vinylpyridinium) salt as new catalyst for the synthesis of spiropyran derivatives and their biological activity. *J. Mol. Catal. A Chem.* **2016**, *425*, 217–228. [[CrossRef](#)]
118. Wu, J.; Shen, Q.; Wang, Y.; Zhao, D.; Peng, C.; Li, J.X. Fluorescent Probes for Subcellular Localization during Osteoclast Formation. *ACS Med. Chem. Lett.* **2014**, *5*, 911–914. [[CrossRef](#)] [[PubMed](#)]
119. Chen, H.; Li, G.; Zhan, P.; Guo, X.; Ding, Q.; Wang, S.; Liu, X. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. *MedChemComm* **2013**, *4*, 827–832. [[CrossRef](#)]
120. Priyanka; Neelabh; Tiwari, N.; Sharma, R.K.; Gupta, P.; Misra, S.; Misra-Bhattacharya, S.; Butcher, R.J.; Singh, K.; Katiyar, D. Synthesis, Structure Elucidation, Homology Modeling and Antifilarial Activity of 7-Benzamidocoumarin Derivatives. *ChemistrySelect* **2019**, *4*, 3300–3307. [[CrossRef](#)]
121. Ostrowska, K.; Lesniak, A.; Gryczka, W.; Dobrzycki, L.; Bujalska-Zadrozny, M.; Trzaskowski, B. New Piperazine Derivatives of 6-Acetyl-7-hydroxy-4-methylcoumarin as 5-HT<sub>1A</sub> Receptor Agents. *Int. J. Mol. Sci.* **2023**, *24*, 2779. [[CrossRef](#)] [[PubMed](#)]
122. Tang, L.; Chen, X.; Kong, X.M.; Liu, T.W.; Feng, X.Q.; Chen, F.E.; Zhuang, Z.H. Anti-aging effect of methylurolithin A and its amide derivatives on nematode *Caenorhabditis elegans*. *Tetrahedron Lett.* **2023**, *118*, 154389. [[CrossRef](#)]

123. Chen, X.; Feng, X.; Kong, X.; Wang, H.; Liu, T.; Tang, L.; Zhuang, Z. Design, synthesis, and anti-aging effect evaluation of urolithin B and its amide derivatives on nematode *Caenorhabditis elegans*. *Med. Chem. Res.* **2023**, *32*, 1087–1097. [[CrossRef](#)]
124. Huang, H.S.; Chen, T.C.; Chen, R.H.; Huang, K.F.; Huang, F.C.; Jhan, J.R.; Chen, C.L.; Lee, C.C.; Lo, Y.; Lin, J.J. Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannulated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues. *Bioorg. Med. Chem.* **2009**, *17*, 7418–7428. [[CrossRef](#)] [[PubMed](#)]
125. Liu, Z.; Zhang, Z.; Zhang, W.; Yan, D. 2-Substituted-1-(2-morpholinoethyl)-1H-naphtho[2,3-d]imidazole-4,9-diones: Design, synthesis and antiproliferative activity. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 2454–2458. [[CrossRef](#)]
126. Wang, P.L.; Cheng, Y.T.; Xu, K.; An, Y.W.; Wang, W.; Li, Q.S.; Han, Q.J.; Li, Q.; Zhang, H.G.; Lei, H.M. Synthesis and antitumor evaluation of one novel tetramethylpyrazine-rhein derivative. *Asian J. Chem.* **2013**, *25*, 4885–4888. [[CrossRef](#)]
127. Li, X.; Lin, Z.; Wang, P.; Zhou, C.; Xu, J.; Lin, J.; Lin, D.; Zhang, D. Tetramethylpyrazine-Rhein Derivative inhibits the migration of canine inflammatory mammary carcinoma cells by mitochondrial damage-mediated apoptosis and cadherins downregulation. *Biomed. Pharmacother.* **2023**, *162*, 114731. [[CrossRef](#)]
128. Ho, S.H.S.; Sim, M.Y.; Yee, W.L.S.; Yang, T.; Yuen, S.P.J.; Go, M.L. Antiproliferative, DNA intercalation and redox cycling activities of dioxonaphtho[2,3-d]imidazolium analogs of YM155: A structure-activity relationship study. *Eur. J. Med. Chem.* **2015**, *104*, 42–56. [[CrossRef](#)] [[PubMed](#)]
129. Premkumar, D.R.; Jane, E.P.; Foster, K.A.; Pollack, I.F. Survivin inhibitor YM-155 sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. *J. Pharmacol. Exp. Ther.* **2013**, *346*, 201–210. [[CrossRef](#)] [[PubMed](#)]
130. Boger, D.L.; Tse, W.C. Thiazole orange as the fluorescent intercalator in a high resolution fid assay for determining DNA binding affinity and sequence selectivity of small molecules. *Bioorg. Med. Chem.* **2001**, *9*, 2511–2518. [[CrossRef](#)]
131. Tse, W.C.; Boger, D.L. A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. *Acc. Chem. Res.* **2004**, *37*, 61–69. [[CrossRef](#)]
132. West, T.J.; Bi, J.; Martinez-Pena, F.; Curtis, E.J.; Gazaniga, N.R.; Mischel, P.S.; Lairson, L.L. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. *J. Am. Chem. Soc.* **2023**, *145*, 8355–8363. [[CrossRef](#)] [[PubMed](#)]
133. Liu, Z.; Yuan, J.; Zhang, Z.; Yan, D.; Zhang, W. Design, synthesis and antitumor activity of 1-monosubstituted 1H-naphth[2,3-d]imidazole-4,9-diones and 1H-anthra[2,3-d]imidazole-4,11-diones. *Chin. J. Org. Chem.* **2018**, *38*, 3302–3317. [[CrossRef](#)]
134. Bargiotti, A.; Musso, L.; Dallavalle, S.; Merlini, L.; Gallo, G.; Ciacci, A.; Giannini, G.; Cabri, W.; Penco, S.; Vesci, L.; et al. Isoxazolo(aza)naphthoquinones: A new class of cytotoxic Hsp90 inhibitors. *Eur. J. Med. Chem.* **2012**, *53*, 64–75. [[CrossRef](#)]
135. Shanab, K.; Schirmer, E.; Knafl, H.; Wulz, E.; Holzer, W.; Spreitzer, H.; Schmidt, P.; Aicher, B.; Mueller, G.; Guenther, E. Synthesis and biological evaluation of new cytotoxic azanaphthoquinone pyrrolo-annulated derivatives. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3950–3952. [[CrossRef](#)]
136. Yu, Q.; Yang, H.; Zhu, T.W.; Yu, L.M.; Chen, J.W.; Gu, L.Q.; Huang, Z.S.; An, L.K. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors. *Eur. J. Med. Chem.* **2018**, *152*, 195–207. [[CrossRef](#)]
137. Shen, D.Q.; Wu, N.; Li, Y.P.; Wu, Z.P.; Zhang, H.B.; Huang, Z.S.; Gu, L.Q.; An, L.K. Design, Synthesis, and Cytotoxicity of Indolizinoquinoxaline-5,12-dione Derivatives, Novel DNA Topoisomerase IB Inhibitors. *Aust. J. Chem.* **2010**, *63*, 1116–1121. [[CrossRef](#)]
138. Devi, L.R.; Raza, K.M.; Musib, D.; Ramu, V.; Devi, J.; Roy, M. Nucleus targeting anthraquinone-based copper (II) complexes as the potent PDT agents: Synthesis, photo-physical and theoretical evaluation. *Inorg. Chim. Acta* **2020**, *500*, 119208. [[CrossRef](#)]
139. Kim, Y.S.; Park, S.Y.; Lee, H.J.; Suh, M.E.; Schollmeyer, D.; Lee, C.O. Synthesis and cytotoxicity of 6,11-Dihydro-pyrido- and 6,11-Dihydro-benzo[2,3-b]phenazine-6,11-dione derivatives. *Bioorg. Med. Chem.* **2003**, *11*, 1709–1714. [[CrossRef](#)]
140. Kim, J.S.; Rhee, H.K.; Park, H.J.; Lee, I.K.; Lee, S.K.; Suh, M.E.; Lee, H.J.; Ryu, C.K.; Choo, H.Y.P. Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. *Bioorg. Med. Chem.* **2007**, *15*, 451–457. [[CrossRef](#)]
141. Lee, H.; Cho, S.; Namgoong, K.; Jung, J.K.; Cho, J.; Yang, S.I. Synthesis and in vitro evaluation of 7-dialkylaminomethylbenzo[g]quinoxaline-5,10-diones. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1235–1237. [[CrossRef](#)] [[PubMed](#)]
142. Kwak, J.H.; Namgoong, K.; Jung, J.K.; Cho, J.; Kim, H.M.; Park, S.G.; Yoo, Y.A.; Kwon, J.H.; Lee, H. Synthesis and cytotoxic activities of 2-alkyl-2,3-dihydro-1H-2,6,9-triazacyclopenta[b]anthracene-5,10-diones. *Arch. Pharmacol. Res.* **2008**, *31*, 995–998. [[CrossRef](#)] [[PubMed](#)]
143. Lee, H.J.; Kim, J.S.; Park, S.Y.; Suh, M.E.; Kim, H.J.; Seo, E.K.; Lee, C.O. Synthesis and cytotoxicity evaluation of 6,11-dihydro-pyridazo- and 6,11-dihydro-pyrido[2,3-b]phenazine-6,11-diones. *Bioorg. Med. Chem.* **2004**, *12*, 1623–1628. [[CrossRef](#)] [[PubMed](#)]
144. Lee, H.-J.; Kim, J.S.; Suh, M.-E.; Park, H.J.; Lee, S.K.; Rhee, H.-K.; Kim, H.J.; Seo, E.-K.; Kim, C.; Lee, C.-O.; et al. Synthesis and cytotoxicity evaluation of substituted pyridazino[4,5-b]phenazine-5,12-diones and tri/tetra-azabenzofluorene-5,6-diones. *Eur. J. Med. Chem.* **2007**, *42*, 168–174. [[CrossRef](#)]
145. Tuyun, A.F.; Bayrak, N.; Yildirim, H.; Onul, N.; Kara, E.M.; Celik, B.O. Synthesis and in vitro biological evaluation of aminonaphthoquinones and Benzo[b]phenazine-6,11-dione derivatives as potential antibacterial and antifungal compounds. *J. Chem.* **2015**, *2015*, 645902. [[CrossRef](#)]

146. Kumar, S.; Kumar, N.; Drabu, S. Synthesis of benzo[g]quinoxaline-5,10-dione based pyrazoline derivatives and their antimycobacterial activity. *Int. J. Pharm. Sci. Res.* **2018**, *9*, 498–508.
147. Kumar, S.; Kumar, N.; Drabu, S. Synthesis of benzo[g]quinoxaline-5,10-dione based pyridine derivatives and their antimycobacterial activity. *Orient. J. Chem.* **2017**, *33*, 821–828. [[CrossRef](#)]
148. Hammam, A.S.; Youssef, M.S.K.; Atta, F.M.; Mohamed, T.A. Synthesis of new quinoxalinophenazinediones and tetrahydrobenzodipyrrolotetrones of biological interest. *Chem. Pap.* **2008**, *62*, 194–206. [[CrossRef](#)]
149. Morin, C.; Besset, T.; Moutet, J.C.; Fayolle, M.; Brueckner, M.; Limosin, D.; Becker, K.; Davioud-Charvet, E. The aza-analogues of 1,4-naphthoquinones are potent substrates and inhibitors of plasmodial thioredoxin and glutathione reductases and of human erythrocyte glutathione reductase. *Org. Biomol. Chem.* **2008**, *6*, 2731–2742. [[CrossRef](#)]
150. Hosoya, Y.; Nojo, W.; Kii, I.; Suzuki, T.; Imanishi, M.; Ohkanda, J. Identification of synthetic inhibitors for the DNA binding of intrinsically disordered circadian clock transcription factors. *Chem. Commun.* **2020**, *56*, 11203–11206. [[CrossRef](#)]
151. Keinan, S.; Paquette, W.D.; Skoko, J.J.; Beratan, D.N.; Yang, W.; Shinde, S.; Johnston, P.A.; Lazo, J.S.; Wipf, P. Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. *Org. Biomol. Chem.* **2008**, *6*, 3256–3263. [[CrossRef](#)] [[PubMed](#)]
152. Besset, T.; Braud, E.; Jarray, R.; Garbay, C.; Kolb, S.; Leo, P.M.; Morin, C. Preparation and evaluation of a set of bis(methoxycarbonylmethio) heteroquinones as CDC25B phosphatase inhibitors. *Eur. J. Chem.* **2011**, *2*, 433–440. [[CrossRef](#)]
153. Yang, H.; Zhu, X.Q.; Wang, W.J.; Chen, Y.; Hu, Z.; Zhang, Y.; Hu, D.X.; Yu, L.M.; Agama, K.; Pommier, Y.; et al. The synthesis of furoquinolinedione and isoxazoquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. *Bioorg. Chem.* **2021**, *111*, 104881. [[CrossRef](#)]
154. Ryu, C.K.; Lee, Y.; Park, S.G.; You, H.J.; Lee, R.Y.; Lee, S.Y.; Choi, S. 3D-QSAR studies of heterocyclic quinones with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment. *Bioorg. Med. Chem.* **2008**, *16*, 9772–9779. [[CrossRef](#)] [[PubMed](#)]
155. Chung, H.J.; Jung, O.J.; Chae, M.J.; Hong, S.Y.; Chung, K.H.; Lee, S.K.; Ryu, C.K. Synthesis and biological evaluation of quinoxaline-5,8-diones that inhibit vascular smooth muscle cell proliferation. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3380–3384. [[CrossRef](#)] [[PubMed](#)]
156. Ye, W.L.; Teng, Z.H.; Liu, D.Z.; Cui, H.; Liu, M.; Cheng, Y.; Yang, T.H.; Mei, Q.B.; Zhou, S.Y. Synthesis of a new pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro. *J. Pharm. Sci.* **2013**, *102*, 530–540. [[CrossRef](#)]
157. Huang, H.; Yan, M.; Chen, J.; Yuan, B.; Chen, G.; Cheng, S.; Huang, D.; Gao, Z.; Cao, C. Identification of ortho-naphthoquinones as anti-AML agents by highly efficient oxidation of phenols. *Bioorg. Chem.* **2019**, *86*, 97–102. [[CrossRef](#)]
158. Sandilya, S.; Das, A.; Deka, S.; Kalita, R. Synthesis, in-vivo anti-inflammatory evaluation and molecular docking study of a series of substituted xanthone derivatives as novel COX-2 inhibitors. *Int. J. Pharm. Sci. Res.* **2021**, *12*, 4491–4503.
159. Zhao, W.; Chen, L.; Li, H.M.; Wang, D.J.; Li, D.S.; Chen, T.; Yuan, Z.P.; Tang, Y.J. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation. *Bioorg. Med. Chem.* **2014**, *22*, 2998–3007. [[CrossRef](#)]
160. Wu, G.R.; Xu, B.; Yang, Y.Q.; Zhang, X.Y.; Fang, K.; Ma, T.; Wang, H.; Xue, N.N.; Chen, M.; Guo, W.B.; et al. Synthesis and biological evaluation of podophyllotoxin derivatives as selective antitumor agents. *Eur. J. Med. Chem.* **2018**, *155*, 183–196. [[CrossRef](#)]
161. Zhang, L.; Zhang, Z.; Chen, F.; Chen, Y.; Lin, Y.; Wang, J. Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways. *Eur. J. Med. Chem.* **2016**, *123*, 226–235. [[CrossRef](#)] [[PubMed](#)]
162. Li, Z.; Su, H.; Yu, W.; Li, X.; Cheng, H.; Liu, M.; Pang, X.; Zou, X. Design, synthesis and anticancer activities of novel otobain derivatives. *Org. Biomol. Chem.* **2016**, *14*, 277–287. [[CrossRef](#)] [[PubMed](#)]
163. Castro, M.A.; Miguel del Corral, J.M.; Gordaliza, M.; Gomez-Zurita, M.A.; de la Puente, M.L.; Betancur-Galvis, L.A.; Sierra, J.; San Feliciano, A. Synthesis, cytotoxicity and antiviral activity of podophyllotoxin analogues modified in the E-ring. *Eur. J. Med. Chem.* **2003**, *38*, 899–911. [[CrossRef](#)] [[PubMed](#)]
164. Zhi, X.Y.; Yang, C.; Zhang, R.; Hu, Y.; Ke, Y.Z.; Xu, H. Natural products-based insecticidal agents 13. Semisynthesis and insecticidal activity of novel phenazine derivatives of 4 $\beta$ -acyloxypodophyllotoxin modified in the E-ring against *Mythimna separata* Walker in vivo. *Ind. Crops Prod.* **2013**, *42*, 520–526. [[CrossRef](#)]
165. Zhi, X.; Yu, X.; Yang, C.; Ding, G.; Chen, H.; Xu, H. Synthesis of 4 $\beta$ -acyloxypodophyllotoxin analogs modified in the C and E rings as insecticidal agents against *Mythimna separata* Walker. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 765–772. [[CrossRef](#)]
166. Zhi, X.; Yang, C.; Yu, X.; Xu, H. Synthesis and insecticidal activity of new oxime derivatives of podophyllotoxin-based phenazines against *Mythimna separata* Walker. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 5679–5682. [[CrossRef](#)]
167. Wang, J.; Zhi, X.; Yu, X.; Xu, H. Synthesis and insecticidal activity of new deoxypodophyllotoxin-based phenazine analogues against *Mythimna separata* Walker. *J. Agric. Food Chem.* **2013**, *61*, 6336–6343. [[CrossRef](#)]
168. Hou, M.; Li, S.; Xu, Z.; Li, B. A Reduction-responsive Amphiphilic Methotrexate-Podophyllotoxin Conjugate for Targeted Chemotherapy. *Chem. Asian J.* **2019**, *14*, 3840–3844. [[CrossRef](#)]
169. Talbot, A.; Maltais, R.; Kenmogne, L.C.; Roy, J.; Poirier, D. Solid-phase synthesis of libraries of ethynylated aminosteroid derivatives as potential antileukemic agents. *Steroids* **2016**, *107*, 55–64. [[CrossRef](#)]

170. Wang, S.; Yuan, X.; Qian, H.; Li, N.; Wang, J. Design, synthesis, and biological evaluation of two series of novel A-ring fused steroidal pyrazines as potential anticancer agents. *Int. J. Mol. Sci.* **2020**, *21*, 1665. [[CrossRef](#)]
171. Tao, H.W.; Peng, W.Y.; Yuan, J.C.; Li, Q.; Zeng, L.Y.; Yu, X.Y.; Yi, P.G. Facile preparation and preliminary cytotoxicity evaluation of dehydroepiandrosterone C-16 spiro-pyrrolidine derivatives. *Chem. Pap.* **2021**, *75*, 823–829. [[CrossRef](#)]
172. Cui, H.W.; Peng, S.; Gu, X.Z.; Chen, H.; He, Y.; Gao, W.; Lv, F.; Wang, J.H.; Wang, Y.; Xie, J.; et al. Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents. *Eur. J. Med. Chem.* **2016**, *111*, 126–137. [[CrossRef](#)] [[PubMed](#)]
173. Handratta, V.D.; Vasaitis, T.S.; Njar, V.C.O.; Gediya, L.K.; Kataria, R.; Chopra, P.; Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; et al. Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, In Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model. *J. Med. Chem.* **2005**, *48*, 2972–2984. [[CrossRef](#)] [[PubMed](#)]
174. Vicker, N.; Lawrence, H.R.; Allan, G.M.; Bubert, C.; Smith, A.; Tutill, H.J.; Purohit, A.; Day, J.M.; Mahon, M.F.; Reed, M.J.; et al. Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids: Inhibitors of 17 $\beta$ -hydroxysteroid dehydrogenase type 1. *ChemMedChem* **2006**, *1*, 464–481. [[CrossRef](#)] [[PubMed](#)]
175. Ivanov, A.; Boldt, S.; un Nisa, Z.; Ali Shah, S.J.; Ehlers, P.; Villinger, A.; Schneider, G.; Woelfling, J.; Rahman, Q.; Iqbal, J.; et al. Synthesis and phosphatase inhibitory activity of 3-alkynylestrones and their derivatives. *RSC Adv.* **2016**, *6*, 11118–11127. [[CrossRef](#)]
176. Bertrand, B.; O'Connell, M.A.; Waller, Z.A.E.; Bochmann, M. A Gold(III) Pincer Ligand Scaffold for the Synthesis of Binuclear and Bioconjugated Complexes: Synthesis and Anticancer Potential. *Chem. Eur. J.* **2018**, *24*, 3613–3622. [[CrossRef](#)]
177. Barrett, S.; De Franco, M.; Kellett, A.; Dempsey, E.; Marzano, C.; Erxleben, A.; Gandin, V.; Montagner, D. Anticancer activity, DNA binding and cell mechanistic studies of estrogen-functionalised Cu(II) complexes. *JBIC J. Biol. Inorg. Chem.* **2020**, *25*, 49–60. [[CrossRef](#)]
178. Khan, S.A.; Asiri, A.M. Synthesis of novel steroidal oxazolo quinoxaline as antibacterial agents. *Arab. J. Chem.* **2010**, *4*, 349–354. [[CrossRef](#)]
179. Khan, S.A.; Saleem, K.; Khan, Z. Synthesis, structure elucidation and antibacterial evaluation of new steroidal -5-en-7-thiazoloquinoxaline derivatives. *Eur. J. Med. Chem.* **2008**, *43*, 2257–2261. [[CrossRef](#)]
180. Khan, S.A. Synthesis, characterization and in vitro antibacterial activity of new steroidal 5-en-3-oxazolo and thiazoloquinoxaline. *Eur. J. Med. Chem.* **2008**, *43*, 2040–2044. [[CrossRef](#)]
181. Dziwornu, G.A.; Kamunya, S.; Ntsabo, T.; Chibale, K. Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: Synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin. *MedChemComm* **2019**, *10*, 961–969. [[CrossRef](#)] [[PubMed](#)]
182. Barrett, S.; Delaney, S.; Kavanagh, K.; Montagner, D. Evaluation of in vitro and in vivo antibacterial activity of novel Cu(II)-steroid complexes. *Inorg. Chim. Acta* **2018**, *479*, 261–265. [[CrossRef](#)]
183. Wang, L.J.; Geng, C.A.; Ma, Y.B.; Huang, X.Y.; Luo, J.; Chen, H.; Guo, R.H.; Zhang, X.M.; Chen, J.J. Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents. *Bioorg. Med. Chem.* **2012**, *20*, 2877–2888. [[CrossRef](#)]
184. Yang, G.X.; Huang, Y.; Zheng, L.L.; Zhang, L.; Su, L.; Wu, Y.H.; Li, J.; Zhou, L.C.; Huang, J.; Tang, Y.; et al. Design, synthesis and evaluation of diosgenin carbamate derivatives as multitarget anti-Alzheimer's disease agents. *Eur. J. Med. Chem.* **2020**, *187*, 111913. [[CrossRef](#)] [[PubMed](#)]
185. Xu, B.; Chu, F.; Zhang, Y.; Wang, X.; Li, Q.; Liu, W.; Xu, X.; Xing, Y.; Chen, J.; Wang, P.; et al. A Series of New Ligustrazine-Triterpenes Derivatives as Anti-Tumor Agents: Design, Synthesis, and Biological Evaluation. *Int. J. Mol. Sci.* **2015**, *16*, 21035–21055. [[CrossRef](#)]
186. Xu, K.; Xu, X.; Chu, F.H.; Wang, M.N.; Wang, P.L.; Li, G.L.; Song, J.X.; Zhang, Y.Z.; Lei, H.M. Synthesis and biological evaluation of T-OA analogues as the cytotoxic agents. *Res. Chem. Intermed.* **2015**, *41*, 6257–6269. [[CrossRef](#)]
187. Xu, B.; Yan, W.Q.; Xu, X.; Wu, G.R.; Zhang, C.Z.; Han, Y.T.; Chu, F.H.; Zhao, R.; Wang, P.L.; Lei, H.M. Combination of amino acid/dipeptide with ligustrazine-betulinic acid as antitumor agents. *Eur. J. Med. Chem.* **2017**, *130*, 26–38. [[CrossRef](#)]
188. Xu, J.; Li, Z.; Luo, J.; Yang, F.; Liu, T.; Liu, M.; Qiu, W.W.; Tang, J. Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption. *J. Med. Chem.* **2012**, *55*, 3122–3134. [[CrossRef](#)]
189. Urban, M.; Sarek, J.; Kvasnica, M.; Tislerova, I.; Hajduch, M. Triterpenoid pyrazines and benzopyrazines with cytotoxic activity. *J. Nat. Prod.* **2007**, *70*, 526–532. [[CrossRef](#)]
190. Haavikko, R.; Nasereddin, A.; Sacerdoti-Sierra, N.; Kopelyanskiy, D.; Alakurtti, S.; Tikka, M.; Jaffe, C.L.; Yli-Kauhaluoma, J. Heterocycle-fused lupane triterpenoids inhibit *Leishmania donovani* amastigotes. *MedChemComm* **2014**, *5*, 445–451. [[CrossRef](#)]
191. Soural, M.; Hodon, J.; Dickinson, N.J.; Sidova, V.; Gurska, S.; Dzubak, P.; Hajduch, M.; Sarek, J.; Urban, M. Preparation of Conjugates of Cytotoxic Lupane Triterpenes with Biotin. *Bioconjug. Chem.* **2015**, *26*, 2563–2570. [[CrossRef](#)]
192. Hodoň, J.; Frydrych, I.; Trhliková, Z.; Pokorný, J.; Borková, L.; Benická, S.; Vlk, M.; Lišková, B.; Kubičková, A.; Medvedíková, M.; et al. Triterpenoid pyrazines and pyridines—Synthesis, cytotoxicity, mechanism of action, preparation of prodrugs. *Eur. J. Med. Chem.* **2022**, *243*, 114777. [[CrossRef](#)] [[PubMed](#)]

193. Suman, P.; Patel, A.; Solano, L.; Jampana, G.; Gardner, Z.S.; Holt, C.M.; Jonnalagadda, S.C. Synthesis and cytotoxicity of Baylis-Hillman template derived betulinic acid-triazole conjugates. *Tetrahedron* **2017**, *73*, 4214–4226. [[CrossRef](#)]
194. Zhang, H.; Wang, Y.; Zhu, P.; Liu, J.; Xu, S.; Yao, H.; Jiang, J.; Ye, W.; Wu, X.; Xu, J. Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid. *Eur. J. Med. Chem.* **2015**, *97*, 235–244. [[CrossRef](#)] [[PubMed](#)]
195. Devendra Rao, S.; Nageswara Rao, B.; Uma Devi, P.; Karteek Rao, A. Isolation of Lupeol, Design and Synthesis of Lupeol Derivatives and their Biological Activity. *Orient. J. Chem.* **2017**, *33*, 173–180. [[CrossRef](#)]
196. Zorina, A.D.; Nikiforova, N.S.; Zarubaev, V.V.; Marchenko, S.A.; Selivanov, S.I.; Starova, G.L.; Mehtiev, A.R.; Rodionov, E.I.; Rodionova, A.A.; Trifonov, R.E. Synthesis, structure and in vitro biological evaluation of new lupane and dammarane triterpenoids fused with pyrazine heterocycle. *Mendeleev Commun.* **2019**, *29*, 500–502. [[CrossRef](#)]
197. Bhandari, P.; Patel, N.K.; Bhutani, K.K. Synthesis of new heterocyclic lupeol derivatives as nitric oxide and pro-inflammatory cytokine inhibitors. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 3596–3599. [[CrossRef](#)]
198. Guo, W.B.; Zhang, H.; Yan, W.Q.; Liu, Y.M.; Zhou, F.; Cai, D.S.; Zhang, W.X.; Huang, X.M.; Jia, X.H.; Chen, H.S.; et al. Design, synthesis, and biological evaluation of ligustrazine—Betulin amino-acid/dipeptide derivatives as anti-tumor agents. *Eur. J. Med. Chem.* **2020**, *185*, 111839. [[CrossRef](#)] [[PubMed](#)]
199. Chu, F.; Xu, X.; Li, G.; Gu, S.; Xu, K.; Gong, Y.; Xu, B.; Wang, M.; Zhang, H.; Zhang, Y.; et al. Amino acid derivatives of ligustrazine-oleanolic acid as new cytotoxic agents. *Molecules* **2014**, *19*, 18215–18231. [[CrossRef](#)] [[PubMed](#)]
200. Wang, P.; Zhang, Y.; Xu, K.; Li, Q.; Zhang, H.; Guo, J.; Pang, D.; Cheng, Y.; Lei, H. A new ligustrazine derivative—Pharmacokinetic evaluation and antitumor activity by suppression of NF- $\kappa$ B/p53 and COX-2 expression in S180 mice. *Pharmazie* **2013**, *68*, 782–789.
201. Qiu, W.W.; Shen, Q.; Yang, F.; Wang, B.; Zou, H.; Li, J.Y.; Li, J.; Tang, J. Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6618–6622. [[CrossRef](#)]
202. Li, J.F.; Zhao, Y.; Cai, M.M.; Li, X.F.; Li, J.X. Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity. *Eur. J. Med. Chem.* **2009**, *44*, 2796–2806. [[CrossRef](#)]
203. Zhang, Y.C.; Shen, Q.; Zhu, M.W.; Wang, J.; Du, Y.; Wu, J.; Li, J.X. Modified Quinoxaline-Fused Oleanolic Acid Derivatives as Inhibitors of Osteoclastogenesis and Potential Agent in Anti-Osteoporosis. *ChemistrySelect* **2020**, *5*, 1526–1533. [[CrossRef](#)]
204. Zhong, Y.Y.; Chen, H.S.; Wu, P.P.; Zhang, B.J.; Yang, Y.; Zhu, Q.Y.; Zhang, C.G.; Zhao, S.Q. Synthesis and biological evaluation of novel oleanolic acid analogues as potential  $\alpha$ -glucosidase inhibitors. *Eur. J. Med. Chem.* **2019**, *164*, 706–716. [[CrossRef](#)]
205. Yang, Y.; Guan, D.; Lei, L.; Lu, J.; Liu, J.Q.; Yang, G.; Yan, C.; Zhai, R.; Tian, J.; Bi, Y.; et al. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. *Toxicol. Appl. Pharmacol.* **2018**, *341*, 98–105. [[CrossRef](#)]
206. Huang, W.; Wang, Y.; Xu, S.; Qiao, H.; Cheng, H.; Wang, L.; Liu, S.; Tian, Q.; Wang, R.; Wang, H.; et al. Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles. *Eur. J. Med. Chem.* **2022**, *232*, 114207. [[CrossRef](#)] [[PubMed](#)]
207. Wang, X.; Ren, Q.W.; Liu, X.X.; Yang, Y.T.; Wang, B.H.; Zhai, R.; Qi, J.G.; Tian, J.W.; Wang, H.B.; Bi, Y. Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents. *Eur. J. Med. Chem.* **2019**, *161*, 364–377. [[CrossRef](#)] [[PubMed](#)]
208. Wang, B.; Liu, S.; Huang, W.; Ma, M.; Chen, X.; Zeng, W.; Liang, K.; Wang, H.; Bi, Y.; Li, X. Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity. *Eur. J. Med. Chem.* **2021**, *211*, 113107. [[CrossRef](#)]
209. Fang, K.; Zhang, X.H.; Han, Y.T.; Wu, G.R.; Cai, D.S.; Xue, N.N.; Guo, W.B.; Yang, Y.Q.; Chen, M.; Zhang, X.Y.; et al. Design, synthesis, and cytotoxic analysis of novel hederagenin-pyrazine derivatives based on partial least squares discriminant analysis. *Int. J. Mol. Sci.* **2018**, *19*, 2994. [[CrossRef](#)] [[PubMed](#)]
210. Wu, P.P.; Zhang, B.J.; Cui, X.P.; Yang, Y.; Jiang, Z.Y.; Zhou, Z.H.; Zhong, Y.Y.; Mai, Y.Y.; Ouyang, Z.; Chen, H.S.; et al. Synthesis and biological evaluation of novel ursolic acid analogues as potential  $\alpha$ -glucosidase inhibitors. *Sci. Rep.* **2017**, *7*, 45578. [[CrossRef](#)]
211. Fu, H.J.; Zhou, Y.R.; Bao, B.H.; Jia, M.X.; Zhao, Y.; Zhang, L.; Li, J.X.; He, H.L.; Zhou, X.M. Tryptophan Hydroxylase 1 (Tph-1)-Targeted Bone Anabolic Agents for Osteoporosis. *J. Med. Chem.* **2014**, *57*, 4692–4709. [[CrossRef](#)] [[PubMed](#)]
212. Shamraiz, U.; Hussain, H.; Ur Rehman, N.; Al-Shidhani, S.; Saeed, A.; Khan, H.Y.; Khan, A.; Fischer, L.; Csuk, R.; Badshah, A.; et al. Synthesis of new boswellic acid derivatives as potential antiproliferative agents. *Nat. Prod. Res.* **2020**, *34*, 1845–1852. [[CrossRef](#)] [[PubMed](#)]
213. Wu, P.; Tu, B.; Liang, J.; Guo, S.; Cao, N.; Chen, S.; Luo, Z.; Li, J.; Zheng, W.; Tang, X.; et al. Synthesis and biological evaluation of pentacyclic triterpenoid derivatives as potential novel antibacterial agents. *Bioorg. Chem.* **2021**, *109*, 104692. [[CrossRef](#)] [[PubMed](#)]
214. Yang, Y.; Zhu, Q.; Zhong, Y.; Cui, X.; Jiang, Z.; Wu, P.; Zheng, X.; Zhang, K.; Zhao, S. Synthesis, anti-microbial and anti-inflammatory activities of 18 $\beta$ -glycyrrhetic acid derivatives. *Bioorg. Chem.* **2020**, *101*, 103985. [[CrossRef](#)]
215. Xu, H.; Tang, H.; Feng, H.; Li, Y. Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide. *Eur. J. Med. Chem.* **2014**, *73*, 46–55. [[CrossRef](#)] [[PubMed](#)]
216. Wei, S.F.; Tang, Y.B.; Hua, H.M.; Ohkoshi, E.; Goto, M.; Wang, L.T.; Lee, K.H.; Xiao, Z.Y. Discovery of novel andrographolide derivatives as cytotoxic agents. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4056–4060. [[CrossRef](#)] [[PubMed](#)]
217. Grigoropoulou, S.; Manou, D.; Antoniou, A.I.; Tsirogianni, A.; Siciliano, C.; Theocharis, A.D.; Athanassopoulos, C.M. Synthesis and Antiproliferative Activity of Novel Dehydroabietic Acid-Chalcone Hybrids. *Molecules* **2022**, *27*, 3623. [[CrossRef](#)] [[PubMed](#)]

218. Zhao, F.; Sun, X.; Lu, W.; Xu, L.; Shi, J.; Yang, S.; Zhou, M.; Su, F.; Lin, F.; Cao, F. Synthesis of novel, DNA binding heterocyclic dehydroabietylamine derivatives as potential antiproliferative and apoptosis-inducing agents. *Drug Deliv.* **2020**, *27*, 216–227. [[CrossRef](#)]
219. De Wang, X.; Li, T.; Li, Y.; Yuan, W.H.; Zhao, Y.Q. 2-Pyrazine-PPD, a novel dammarane derivative, showed anticancer activity by reactive oxygen species-mediate apoptosis and endoplasmic reticulum stress in gastric cancer cells. *Eur. J. Pharmacol.* **2020**, *881*, 173211. [[CrossRef](#)]
220. Xu, S.; Li, D.; Pei, L.; Yao, H.; Wang, C.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2811–2814. [[CrossRef](#)]
221. Xu, S.; Pei, L.; Li, D.; Yao, H.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives. *Fitoterapia* **2014**, *99*, 300–306. [[CrossRef](#)] [[PubMed](#)]
222. Chen, P.; Zhang, D.; Li, M.; Wu, Q.; Lam, Y.P.Y.; Guo, Y.; Chen, C.; Bai, N.; Malhotra, S.; Li, W.; et al. Discovery of novel, potent, isosteviol-based antithrombotic agents. *Eur. J. Med. Chem.* **2019**, *183*, 111722. [[CrossRef](#)]
223. Bruno, M.; Rosselli, S.; Pibiri, I.; Kilgore, N.; Lee, K.H. Anti-HIV Agents Derived from the ent-Kaurane Diterpenoid Linearol. *J. Nat. Prod.* **2002**, *65*, 1594–1597. [[CrossRef](#)] [[PubMed](#)]
224. Khusnutdinova, E.F.; Smirnova, I.E.; Kazakova, O.B.; Petrova, A.V.; Ha, N.T.T.; Viet, D.Q. Synthesis and evaluation of 2,3-indolotriterpenoids as new  $\alpha$ -glucosidase inhibitors. *Med. Chem. Res.* **2017**, *26*, 2737–2742. [[CrossRef](#)]
225. Nishiyama, H.; Ono, M.; Sugimoto, T.; Sasai, T.; Asakawa, N.; Ueno, S.; Tominaga, Y.; Yaegashi, T.; Nagaoka, M.; Matsuzaki, T.; et al. 4-Chlorocolchicine derivatives bearing a thiourea side chain at the C-7 position as potent anticancer agents. *MedChemComm* **2014**, *5*, 452–458. [[CrossRef](#)]
226. Li, Q.; Zu, Y.; Shi, R.; Yao, L.; Fu, Y.; Yang, Z.; Li, L. Synthesis and antitumor activity of novel 10-substituted camptothecin analogues. *Bioorg. Med. Chem.* **2006**, *14*, 7175–7182. [[CrossRef](#)]
227. Zhou, T.; Hou, J.; Wang, M.; Ma, L.; Wu, L.; Wang, S.; Sun, B.; Yao, Z.J. Regio-controlled synthesis of unsymmetrical pyrazine-fused sinomenine derivatives and discriminate substitution effects on TNF- $\alpha$  inhibitory activity. *Tetrahedron* **2014**, *70*, 5475–5482. [[CrossRef](#)]
228. Lou, Y.T.; Zhou, H.B.; Zou, J.; Yan, L.C.; Bi, E.G.; Sun, B.; Yao, Z.J. Modification of poorly bioactive sinomenine into more potent immunosuppressive agents by embedding of drug-like fragments. *Tetrahedron Lett.* **2010**, *51*, 485–488. [[CrossRef](#)]
229. Watanabe, Y.; Hayashida, K.; Saito, D.; Takahashi, T.; Sakai, J.; Nakata, E.; Kanda, T.; Iwai, T.; Hirayama, S.; Fujii, H.; et al. Design and synthesis of novel  $\delta$  opioid receptor agonists with an azatricyclodecane skeleton for improving blood-brain barrier penetration. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 3495–3498. [[CrossRef](#)]
230. Yekkirala, A.S.; Lunzer, M.M.; McCurdy, C.R.; Powers, M.D.; Kalyuzhny, A.E.; Roerig, S.C.; Portoghese, P.S. N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of  $\mu$ /kappa-opioid heteromers. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 5098–5103. [[CrossRef](#)]
231. Le Naour, M.; Lunzer, M.M.; Powers, M.D.; Portoghese, P.S. Opioid Activity of Spinally Selective Analogues of N-Naphthoyl- $\beta$ -naltrexamine in HEK-293 Cells and Mice. *J. Med. Chem.* **2012**, *55*, 670–677. [[CrossRef](#)] [[PubMed](#)]
232. Huang, X.; Deng, H.; Shen, Q.K.; Quan, Z.S. Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications. *Curr. Med. Chem.* **2022**, *29*, 1959–1989. [[CrossRef](#)] [[PubMed](#)]
233. Rodrigues, T.; Reker, D.; Schneider, P.; Schneider, G. Counting on natural products for drug design. *Nat. Chem.* **2016**, *8*, 531–541. [[CrossRef](#)] [[PubMed](#)]
234. Xu, Q.; Deng, H.; Li, X.T.; Quan, Z.S. Application of Amino Acids in the Structural Modification of Natural Products: A Review. *Front. Chem.* **2021**, *9*, 650569. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.